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Chapter 1 
1.1.1 Lung Cancer Overview  
The genesis of the word cancer can be attributed to the Greek physician 
Hippocrates (460 - 370 B.C.), who is regarded as the “Father of Medicine.”  His 
detailed study used the terms karkinos and karkinoma to distinguish non-ulcer 
forming and ulcer forming tumors [1].  The Greek definition of karkinos is crab, 
which among many other explanations is thought to describe the outward 
projections from a cancer akin to that resembling the shape of a crab. Centuries 
later, the Greek word was translated into Latin by the roman physician, Celsus 
(28 - 50 B.C.) giving us the modern word cancer [2].   
Advancing twenty-two centuries, we now define cancer as the transformative 
biological response of a cell to both genetic and epigenetic changes shaped by 
environmental cues that together lead to uncontrolled cell proliferation and 
survival.  This is a disease fundamentally occurring at the cellular level, and 
when compared to normal cells differ in a number of ways: control of growth, 
morphology, cell-cell interaction, membrane and cytoskeletal composition, 
protein synthesis, and gene expression [3]. 
At the causative core of these differences are two broad classes of genes 
that play an elementary role in the transformative progression to cancer called 
proto-oncogenes and tumor-suppressor genes.   Oncogenes can be generally 
defined as any gene product capable of transforming cells.  Proto-oncogenes 
play am evolutionarily conserved role in normal signaling networks controlling 
cellular differentiation, growth, survival and maintenance of tissues.  Activation of 
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a proto-oncogene into an oncogene occurs through gain-of-function mutations 
that now express an oncoprotien capable of driving transformation process.  
Conversely, tumor-suppressor genes normally encode proteins that through 
various mechanisms act to limit cell proliferation [4].  These include proteins 
responsible for cell cycle control, and DNA repair, as well as critical mediators of 
apoptosis, among others.  It is important to note that tumor-suppressor genes are 
recessive with regard to activity, meaning both copies of tumor-suppressor gene 
must be lost or inactivated to drive tumor progression.   Familial inheritance of 
single copy mutant alleles for tumor suppressors, such as RB, APC, and BRCA1, 
dramatically increases the probability of a select tumor initiation [5].  Progression 
of cancers is highly variable and is dependent on a number of factors: namely the 
particular molecular drivers of disease, tissue of origin, immune system function, 
and micro-environmental cues [6].   
 As with other cancers, current treatment options for lung cancer are 
largely based upon stage of cancer upon diagnosis, however other factors such 
as overall health and lung function are important.   For early stage (stage I/II) 
disease non-small cell lung cancer (NSCLC) patients are most likely to undergo 
surgery alone or in conjunction with adjuvant chemotherapy [7].  Patients with 
stage III diagnosis represent a heterogeneous group and treatment options are 
limited to the location of the tumor and whether surgery is possible.  Patients may 
present disease ranging from resectable tumors with microscopic lymph node 
metastasis to large tumors involving multiple lymph nodes. Stage III NSCLC is 
addressed similar to early disease, albeit in a more aggressive manner with 
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increased use of radiotherapy or adjuvant chemotherapy.   For newly diagnosed 
NSCLC, 40% of patients are found to have stage IV disease [8]. Treatment goals 
and options for stage IV NSCLC are no longer curative but rather to prolong 
survival and control cancer related symptoms.  The first-line therapy for patients 
with advanced NSCLC are cytotoxic combination chemotherapy using a platinum 
based doublet (cisplatin or carboplatin) in tandem with a cytotoxic agents such as 
paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan and pemetrexed [9, 
10]. More recent clinical studies also indicate potential benefit of adding 
molecularly targeted inhibitors, bevacizumab or cetuximab, to the cytotoxic 
combination chemotherapy [11].  For patients having identified EGFR mutations, 
the use of EGFR tyrosine kinase inhibitors (TKIs) are indicated as a first-line 
treatment, in addition to second- or third-line treatment for advanced NSCLC [12, 
13]. In this era of molecular therapeutics, the discovery of clinically responsive 
EGFR mutations found in a small subset of lung adenocaricinomas and the 
promise of EGFR targeted therapeutics stands as model for future personalized 
care for advanced stage cancers.  We now realize the clinical practice is 
gradually shifting from therapy based on clinicopathologic features to 
implementation of biomarker driven treatments based on a molecular profile of a 
patient’s tumor. 
 
1.1.2 Lung cancer etiology and epidemiology 
Exactly 50 years ago the landmark publication “Smoking and Health: 
Report of the Advisory Committee to the U.S. Surgeon General of the Public 
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Health Service” concluded that cigarette smoking is a cause of lung cancer in 
men and sufficient in scope to demand “remedial action” for the betterment of 
society [14].  The call to action outlined in the 1964 report was followed by 
increased public awareness and shift in attitudes to smoking related health risks. 
In subsequent years, further action to increase regulatory oversight of use, sales, 
and advertising of tobacco products. The current Surgeon General report now 
concludes that active cigarette smoking is a cause of 1.) nine types of cancer, 2.) 
cardiovascular disease, 3.) chronic obstructive pulmonary disease, 4.) acute 
respiratory illness, 5.) respiratory effects having adverse impact on lung growth 
and function,  6.) reproductive associated complications, as well as numerous 
other deleterious health effects [15, 16].  
Lung cancer was once considered a rare disease, however the onset of 
mechanization and wide scale marketing at the end of the 19th century brought 
cigarette smoking to the mainstream leaving behind a lung cancer epidemic [17]. 
The worldwide burden of lung cancer attributable to smoking is 80% for males 
and greater than 50% for females [18].  Lung cancer is now the leading cause of 
cancer-related death both in the United States and globally, accounting for 
228,190 new diagnosis and 150,480 deaths in the United States for 2013 alone. 
[19, 20].  According to a 2012 Centers for Disease Control (CDC) study the 
Commonwealth of Kentucky was ranked first among all states for having the 
most adult cigarette smokers [21].  As a matter of public health, it is incumbent 
on our federal, state, and local officials to engage in anti-smoking efforts at all 
levels, knowing the best way to prevent lung cancer is to not smoke. 
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Tobacco smoke is composed of greater than 60 known carcinogens, with 
nearly half of which having a strong association with the development of lung 
cancer [22].   Among these carcinogens the  best studied are the damaging 
effects of polycyclic aromatic hydrocarbons and the tobacco-specific nitrosamine 
4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone, each of which introduce 
mutations via DNA adduct formation [23].  Chronic exposure to the carcinogens 
found in tobacco smoke eventuates mutations in critical genes such as p53 and 
K-RAS, which may serve as an initiating event or contribute to the progression of 
disease.  Secondary causes of lung cancer are attributable to workplace agents 
such as asbestos, chromium, nickel, arsenic, and radon, as well as 
environmental factors such as second hand smoke and air pollution [24]. 
There are primarily two histologically distinct  forms of lung cancer, non-
small cell lung cancer (NSCLC) accounting for 85% and small cell lung cancer 
(SCLC) representing approximately 15% of all lung cancers [25].  The 
overwhelming majority of lung cancer patients with NSCLC (85%) or SCLC 
(98%) are current smokers [26].   NSCLCs are further divided into three major 
sub-types, squamous cell carcinoma (SCC), adenocarcinoma (ADC), and large 
cell carcinomas (LCC).  Lung adenocarcinoma is most common histological 
subtype of lung cancer accounting for nearly 40% of all lung cancer [27].   
 
1.1.3  Lung cancer genetics 
  Significant advances have been made in delineating the cellular and 
molecular mechanisms directing tumor initiation, maintenance, and progression 
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of lung cancer.  Susceptibility and risk of lung cancer been shown to have strong 
correlation with hereditary genetic factors, this is underscored by the observation 
that only 10-20% of smokers develop lung cancer [28].   Epidemiological studies 
indicate a 2.5 fold increase in risk of developing lung cancer related to a family 
history of lung cancer [29]. These risks are associated with common inherited 
cancer syndromes such as germ-line inactivating mutations in tumor suppressor 
genes TP53 and RB among others [30, 31].  However, loss-of-function mutations 
in these genes are common to a variety of cancers, and to date no conclusive 
familial link specific to the development lung cancer has been identified. 
Apart from the familial predisposition to the development of lung cancer, 
environmental factors such as tobacco smoke cause DNA lesions directly 
involved in tumor initiation and progression.  Large scale genomic studies 
indicate a given lung tumor is comprised of a large number of somatic mutations 
that occur over time [32, 33].  Indeed, both histologically normal bronchial 
epithelial cells and pre-neoplastic cells express many of these genetic and 
epigenetic abnormalities, suggesting human lung cancers arise from normal 
epithelium through a multistep accumulation of successive genetic and 
epigenetic changes [34].  Among the most common, and best studied of these 
related to the pathogenesis of lung cancer are the tumor suppressor TP53, and 
the proto-oncogenes RAS and EGFR. 
TP53 (encoding protein p53) is the most frequently mutated gene in 
human cancer.  Wild-type p53 functions as a sensor that determines cell fate by 
orchestrating the cellular response (DNA repair or apoptosis) to cell stress and 
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DNA damage.  As a transcription factor, activated p53 promotes the expression 
of cell cycle inhibitory proteins causing G0/G1 cell cycle arrest and the induction 
of apoptosis [35] . When p53 is compromised, no longer can cells detect DNA 
damage and appropriately dictate the cellular responses needed, thus increasing 
the likelihood for acquiring DNA lesions and increasing overall genomic 
instability. Mutations in TP53 are present in approximately 50% of NSCLC 
tumors and 90% of SCLC cancers [24].   Therefore, loss of p53 can be viewed as 
a critical step influencing the development of lung cancer.  
 
Proto-oncogenes in lung cancer 
The deregulated signaling pathways that result directly or indirectly from 
the variety genetic mutations involved in lung cancer are important targets for 
current and future cancer therapies.  The oncogenic signaling molecules and 
related pathways involved are common among many human cancer types 
besides lung cancer such as KRAS, EGFR, PIK3CA, BRAF, HER2 and EML-
4ALK [36].   
As a cancer develops these deregulated growth signals often lead to 
“oncogenic addiction,” whereby the tumor becomes completely reliant on these 
signals for survival.  Consequently, if these oncogenic signals are blocked (e.g. 
by targeted drugs) those addicted cancers will die, whereas those cells not 
dependent remain largely insensitive to the particular drug activity [37].  The 
concept of targeted inhibition of tumor specific oncoproteins has led to 
tremendous genome wide sequencing and simultaneous drug development 
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efforts, to both identify, and develop rational therapeutics.  The remainder of this 
section will focus those driver oncogenes most common to lung cancers, EGFR 
and K-RAS, and their interaction with PI3K signaling pathway.    
 
Oncogenic EGFR signaling in lung cancer 
The epidermal growth factor receptor (EGFR/ERBB1/HER1) is an important 
member of the cell surface receptor super-family of receptor tyrosine kinases 
(RTKs) that are critical mediators of cell signaling by extracellular growth factors.    
In addition to EGFR, the other family members include ERBB2/HER2, 
ERBB3/HER3 and ERBB4/HER4, each of which have garnered much attention 
provided their association with the development and progression of many human 
tumors [38].  The EGFR proto-oncogene plays an important role in normal cell 
proliferation, apoptosis, and angiogenesis, both the receptor and its ligands are 
frequently overexpressed in the development and maintenance of non-small cell 
lung cancer (NSCLC) [39, 40].    
Over the past decade, the development of small molecule inhibitors of  
EGFR activity were developed as anti-cancer agents, these being erlotinib (OSI 
Pharmaceuticals) and gefitinib (AstraZeneca) [41, 42] .  Subsequent studies 
indicated a subset of patients with chemo-refractory NSCLC demonstrated 
dramatic, though often not sustained response to inhibitors of EGFR [43] .  
Among those patients exhibiting tumor regressions, response was found to 
correlate with mutations of EGFR found in the kinase domain (exons 18-24) of 
the molecule [44, 45].    EGFR kinase domain mutations are restricted to only a 
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subset of NSCLC, comprising approximately 10-20% of NSCLC cases [46, 47].  
Deletions in exon 19 (most often del746-750) and point mutations in exons 18 
(G718A/C), 20 (T790M) and 21 (L585R) lead to the increased and sustained 
activation of the receptor [48].  Downstream of mutant EGFR are the PI3K/AKT, 
RAS/MAPK, and STAT pathways, which are regulated and dependent on the 
deregulated EGFR signaling [49].   Treatment with EGFR-TKIs in these “EGFR 
addicted” NSCLC tumors shuts down the growth and survival signaling through 
these pathways and cells undergo considerable apoptosis.   However, significant 
initial tumor regressions are only temporary in response to EGFR-TKI treatments; 
these cancers inevitably become resistant to therapy within 12 months [50-52].    
However, complicating this effort are the approximately 10-20% of patients who 
do demonstrate a partial response to EGFR-TKI, but do not have identifiable 
EGFR mutations, suggesting that other mechanisms and pathway activity apart 
from mutant EGFR underlie responsiveness [53, 54]. 
  Such insights into EGFR-dependent signaling highlight the ongoing 
difficulty in identifying clinically suitable patient populations for EGFR-TKI therapy 
and the potential for rational combination therapies targeting other compensatory 
drivers of disease. 
 
Mutant K-RAS signaling in lung cancer  
Approximately 30% of human tumors harbor RAS gene mutations [55], this 
includes a high prevalence in lung cancers at approximately 25-50% [56, 57]. 
The RAS family of proto-oncogenes (H-RAS, K-RAS, and N-RAS) are membrane 
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associated small G proteins that regulate critical signaling responsible for normal 
cell proliferation, differentiation, and survival [58-60] . The RAS proteins 
functionally serve as a link between the upstream receptor tyrosine kinases 
(RTKs), and the downstream serine/threonine kinases of MAPK pathway [61, 
62].   RAS also plays an important role upstream of PI3K signaling, acting as a 
positive regulator of PI3K activation [63].  GDP-bound RAS is inactive, however 
conversion to active state, GTP-bound RAS, is carried out by guanine nucleotide 
exchange factors (GEFs).  GTPase-activating proteins (GAPs) return RAS to 
inactive state by hydrolyzing GTP into GDP.     
 Mutations affecting KRAS represent greater than 90% of RAS mutations 
found in NSCLC, most having single base pair mutations in codons 12 and to a 
lesser extent codon 13 which makeup the guanine binding domain of RAS [64].  
Furthermore, lung adenocarcinomas having activating mutations in codons 12 
and 13 of KRAS are almost entirely found in patients with a history of cigarette 
smoking [65, 66], whereas EGFR mutations are more common in never smokers 
[28, 33].  Mechanistically, these mutations lock the RAS protein into the active 
GTP-bound conformation that leads to persistent signaling downstream via 
PI3K/AKT/mTOR and RAF/MEK/ERK pathway effectors leading to sustained 
proliferative and pro-survival signaling.  Attempts to develop targeted inhibitors of 
RAS have thus far been unsuccessful which has made treatment of RAS mutant 
cancers difficult.  Current drug discovery efforts are now aimed downstream of 
activated RAS, as indicated by the clinical emergence of RAF and MEK kinase 
inhibitors [67-69].   
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1.2  THE BIOLOGY OF PI3K 
Phosphoiositide-3-kinases (PI3Ks) form a family of lipid kinases that 
functionally generate intracellular phospholipid species that affect a wide range of 
biological activities.  Specifically, activated PI3Ks phosphorylate the 3-OH group 
of membrane lipid phosphatidylinositol (4,5) bisphosphate (PIP2) to form 
phosphatidylinositol (3,4,5) triphosphate (PIP3) that function as second 
messengers providing both specific spatial and temporal signals that modulate 
the activity of intracellular protein effectors responsible for a wide range of 
cellular functions [70-74] .   
 A large body of research has identified an evolutionarily conserved family 
of PI3K enzyme organized into 3 classes (Class I, Class II, and Class III) on the 
basis of structural characteristics, tissue distribution, regulation, and lipid 
substrate preference.  The best characterized of these, Class I PI3Ks are 
composed of p110α (PIK3CA), p110β (PIK3CB), p110γ (PIK3CG), and p110δ 
(PIK3CD) [75-77].  Class II PI3Ks PI3K-C2α (PIK3C2A), PI3K-C2β (PIK3C2B), 
PI3K-C2γ (PIK3C2G) remain elusive, having are poorly understood roles in cell 
signaling [78] .  Finally, Class III PI3K is only comprised of VPS34 (PIK3C3), 
which initial studies report having a role in endosomal sorting of proteins [79]. 
The isoform specific functional activities of the class I PI3Ks and involvement in 
human cancers will largely be the focus of further discussion below.   
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1.2.1 Class I PI3Ks 
Structural organization of p85:p110 heterodimers 
The catalytic p110 subunits are further sub-divided into class IA composed 
of (p110α, p110β, p110δ), each associating with the p85-type (p85α or p85β) of 
regulatory subunit, whereas class IB sub-group (p110γ) binds either p101 or p87 
regulatory subunits [80-82]. 
The class IA regulatory p85 α/β and catalytic p110 α/β/δ are multi-domain 
proteins that functionally interact with upstream and downstream effectors 
(Figure 1.1.).  The full length p85 isoforms, α or β, are composed of N-terminal 
Src homology 3 domain (SH3) then a breakpoint cluster region (BCR) homology 
domain flanked by proline rich domains, and three SH2 domains (nSH2, iSH2 
and cSH2) [71].  The p110 catalytic subunit is composed of N-terminal adaptor 
binding domain (ABD), Ras binding domain (RBD), C2 core structure, helical 
domain and the kinase domain [83] (Figure 1.1.). 
Activation of class IA PI3Ks is strictly regulated by the obligate regulatory 
subunits association with the catalytic subunit [84].  Importantly, the regulatory 
interactions of p85 that control enzymatic activity differ depending on the 
particular class IA p110 isotype to which it is associated.  Regulation of p110α 
and δ catalytic activity is mediated by two groups of inhibitory contacts:  (I) SH2 
(N-terminal SH2) domains of 85α make contacts with the helical domain, C2, and 
the kinase domain; and (II) the iSH2 (inter- SH2) domain of p85 forming inhibitory 
contacts with the ABD and C2 domains of p110α (Figure 1.1.; solid lines 1 & 2) 
[83].    The c-SH2 (C-terminal SH2) of p85 does not provide any inhibitory 
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involvement in for the p110α isoform.   However, for p110β this is not true, in 
addition to the regulation by the nSH2 and iSH2 contacts, p110β has an 
additional inhibitory contact between cSH2 domain of p85 and the kinase domain 
(Figure 1.1., dashed line 3).    These differences in p85:p110 regulation unique to 
p110α/δ and p110β comprise functional molecules that have very different 
interaction and activation requirements among the PI3K isoforms which 
ultimately impart isoform specific function in cells [85-87]. 
 
Regulatory and catalytic mechanism of PI3Ks 
A common feature of PI3K and other protein kinases are the shared bi-
lobal structural organization of the kinase domains where ATP is bound between 
the lobes [88].   The N-terminal lobe of PI3Ks is composed of highly conserved 
five-stranded β-sheet and the regulatory element kα3 helix oriented tightly along 
the helical and ABD domains [89].  The C-terminal lobe is composed of mostly α-
helices that are oriented to allow for membrane interaction, receptivity of lipid 
substrates, and the p85 regulatory subunit [87].  A distinct structural element of 
the C-lobe are the kα10, kα11, and kα12 helices which make up the regulatory 
arch that encloses the activation and catalytic loops required for catalysis [90].    
Multiple confirmations of kα12 helices have been identified, which have been 
attributed to its central role in membrane binding and thus the overall activity of 
the kinase [91].  The helix is thought to maintain the closed-inactive conformation 
of the enzyme in absence of lipid membrane, thus limiting substrate access to 
the active site.  The kα10, kα11, kα10 helices of the regulatory arch are also 
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important because they interact with nSH2 and cSH2 of p85 as well as other 
regulatory proteins that modify the active confirmation of catalytic loop [92].  The 
catalytic domains of PI3K are spatially oriented by the conserved hydrophobic 
domains called the regulatory (R-spine) and catalytic spine (C-spine).  Together 
these build the scaffold for the catalytic loop and placement of ATP [90, 93].  
Thus, in the presence of membrane lipid substrate, binding by the activation loop 
and helix kα12 causes the conformation change needed fully accommodate the 
lipid substrate, and simultaneously relieves inactive confirmation in the catalytic 
center to its fully active state [87] .   
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  The domain structures and regulatory interactions of class IA 
PI3Ks.  Illustration depicts the interaction of class IA PI3K heterodimers with 
various upstream signaling molecules known to activate PI3K.  Solid Black and 
grey lines (1 & 2) represent common inhibitory contacts between p85 regulatory 
and p110 catalytic subunits.  Dashed line (3) represents a unique third inhibitory 
contact found only in p85:p110β interaction.   
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1.2.2 Canonical Class I PI3K activation  
The canonical PI3K signaling pathway can be activated by RTKs (with or 
without adaptor molecules), RAS, or GPCRs (Figure 1.2.).  
 
Activation by receptor tyrosine kinases 
In quiescent cells, cytosolic PI3K p110 catalytic subunits are stabilized 
and sustained in the inactive state by p85 regulatory subunit interaction. Upon 
growth factor stimulation, receptor tyrosine kinases (RTKs) can activate class I 
PI3K through the binding interaction between the SH2 domains (Rous-sarcoma-
oncogene homology-2 domains) of the p85 regulatory subunit with 
phosphorylated-tyrosine (pYXXM) motifs of the receptor, or via receptor 
associated adaptor molecules [94, 95]. The phospho-tyrosine (pY) – SH2 
engagement releases imposed inhibition of p110 catalytic site, and them into 
close proximity to membrane resident lipid substrate phosphatidylinositol 4, 5,-
biphosphate (PIP2) to generate phosphatidylinositol 3, 4, 5,-triphosphate (PIP3) 
[96-98]. 
 
Activation by RAS super family of G proteins 
RAS activation of class I PI3Ks occurs through a direct binding with the 
RAS binding domain (RBD) of the p110 catalytic subunit [99-101]. However, 
activation is not uniform for all PI3K isoforms.  Differential activation of PI3Ks is 
thought to be dependent on the particular RAS family members involved, or in 
the degree of activation among the PI3K isoforms, due in large part to the 
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marked sequence variation among the isoforms in the RBD of p110 [90, 102, 
103]. The canonical activation of PI3K through RAS occurs in conjunction with 
activated RTKs, the recruitment of adaptor molecule growth factor receptor-
bound protein 2 (GRB2) and the guanine nucleotide exchange factor (GEF) 
protein son-of-sevenless (SOS).  This signaling complex both activates and 
brings RAS into proximity with p110 PI3K [100, 104].  RAS mediated activation of 
p110α can be restricted by p85, however this inhibition can be released in 
response to p85 SH2 domain binding to (pY) motifs [105].  This suggests RAS 
activation of PI3K is a tightly orchestrated event, where p85 regulatory subunit 
can modulate responsiveness to RAS by sequential activation of catalytic 
subunits by RTKs, and that class IA PI3Ks may only be responsive to RAS after 
prior RTK activation.   
 
G-protein-coupled receptor mediated activation of PI3K 
 The superfamily of heterotrimeric G-protein-coupled receptors (GPCRs) 
are cell surface signaling proteins involved in a wide range of physiological 
functions and diseases, including cancer development and metastasis [106]. 
Among the class IA PI3K isotypes, p110β is uniquely found to be activated by 
GPCRs [107, 108].   Binding and activation of p110β occurs through direct Gβγ 
heterodimer interaction with the catalytic p110 subunit occurring independently of 
p85 regulatory subunit [109, 110]. 
In addition to direct PI3K activation, the functional cross-talk between 
GPCRs and growth factor receptors is reported to contribute to the progression 
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of lung, breast, colon, prostate, and head and neck tumors by activation of PI3K 
[111].  Multiple GPCRs are found capable to transactivate EGFR signaling by 
promoting autocrine and paracrine release of EGF-like ligands [112, 113]. The 
GPCR-induced growth factor shedding is mediated by members of ADAM (a 
disintegrin and metalloproteinase) family of zinc-dependent proteases, most 
noteworthy being the tumor necrosis factor-α (TNFα) converting enzyme (TACE) 
[114].  Taken together, in solid tumors the GPCR driven PI3K signaling is 
mediated directly through the p110β isoform, and can drive particular growth 
factor signaling upstream of PI3K by transactivation of receptor tyrosine kinases 
such as EGFR.  
 
Effectors of PI3K signaling 
The oncogenic nature of PI3K pathway signaling is the result of 
interactions that deregulate transcription and translation controls responsible for 
cell mass and cell cycle progression, as well as the direct modulation of pro-
survival signaling [115].  Aberrant activation of PI3K/AKT signaling is a common 
feature to NSCLC, playing a critical role in the initiation and progression of the 
disease. [116-118].  The deregulated hyperactivation of AKT is observed in most 
NSCLC cell lines and NSCLC tumors [35, 36], and found to promote resistance 
to chemotherapy and radiotherapy [119, 120].   Recent characterization of AKT in 
lung cancer cell lines identified persistent activation of AKT attributed to PTEN 
loss, activating mutations in EGFR or PIK3CA, or amplification of ERBB2 [118]. 
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The Ser/Thr kinase AKT (the mammalian homologue of the retroviral 
transforming protein v-Akt, or also known as PKB, due its homology to PKA and 
PKC) is the best studied effector of PI3K, as it was among the first proteins found 
to contain the pleckstrin homology (PH) domain required for phosphoinositide 
binding [121, 122].  The PH domain was shown to bind to phosphatidylinositol 
4,5 P2, and AKT is rapidly activated by growth factors and dependent on 
upstream PI3K lipid kinase activity [123].   The generation of phosphatidylinositol 
3,4,5 P3 and phosphatidylinositol 3,4  P2 can directly bind to the PH domain of 
AKT allowing for activation phosphorylation at Thr308 by phosphoinositide-
dependent kinase 1 (PDK1) [124-126].   However, initiating Thr308 
phosphorylation is required for partial activation; an additional phosphorylation at 
Ser473 is needed for full AKT activation [127].   The phosphorylation at Ser473 is 
carried out by the mammalian target of rapamycin complex 2 (mTORC2) [128, 
129].   
  Now 20 years since the discovery of AKT, we appreciate the central role 
as an effector of PI3K that is frequently activated in cancer leading to 
deregulated metabolism, proliferation and apoptosis (Figure 1.2.).  The PI3K 
dependent activation of AKT occurs in 2 peaks affecting cell growth and G1 cell 
cycle progression. The first occurs within minutes of growth factor stimulation (at 
the G0/G1 transition), and second occurring in advanced stage of G1 phase [130-
132].  Activated AKT has a number of direct substrates that have critical roles in 
transcriptional regulation of the cell cycle.  Prominent examples are the cell cycle 
inhibitor protein p27 (also known as KIP1), the forkhead box transcription factors 
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(FOXO), glycogen synthase kinase 3 (GSK3), serum and glucocorticoid-induced 
kinase 1 (SGK1), tuberous sclerosis complex 2 (TSC2) and nuclear factor kB 
(NFκB) [133-135].  Upregulated PI3K/AKT signaling regulates cyclin-dependent 
kinase (Cdk) activity by inducing cyclin D synthesis and blocking its degradation, 
an effect directed by the inhibitory AKT phosphorylation of GSK3β [136].   Cell 
cycle entry is mediated by PI3K/AKT signaling through FOXO transcription factor 
controlled expression of cyclin G2 and p27 [137, 138].  Another important 
molecule inactivated by AKT phosphorylation is TSC2, which functionally 
connects the activation of PI3K with mTOR signaling.  Active TSC2 is 
unphosphorylated (Ser939 and T1462), whereby it heterodimerizes with TSC1 to 
negatively regulate GTPase activity of the Ras-like small GTP-binding protein 
RHEB [139, 140].  The active GTP-bound RHEB can directly interact to positively 
regulate mTORC1 (mammalian target of rapamycin complex 1) [141] .  In 
addition to TSC2, AKT activates mTOR by phosphorylating regulatory protein 
subunit PRAS40 (proline-rich AKT substrate of 40kDa) (Ser246) to alter the 
inhibitory raptor-PRAS40 interaction [142].  
The protein kinase TORC1 functions as an evolutionarily conserved 
environmental sensor.  This multifunctional protein integrates to cellular energy 
and nutrient status and diverse environmental cues such as growth factors, 
hormones and mitogens to coordinate the proper homeostatic cellular responses.  
The PI3K/AKT activation of TORC1 promotes POL I- and POL III- RNA 
polymerase dependent transcription, thus regulating the abundance of protein 
synthesis machinery in the cell [143, 144].  Furthermore, mTORC1 can directly 
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regulate protein synthesis by phosporylating effectors S6K (p70 S6 kinase) and 
4EBP (translation initiation factor 4E-binding protein) proteins [145]. 
 To date, TOR is known to exist as two multi-subunit complexes known as 
TORC1 (TOR complex 1) and TORC2 (TOR complex  2) [146] .  These TORC 
complexes demonstrate distinct protein constituents, substrate specificity, 
regulation, and sensitivity to rapamycin [147].  The mammalian mTORC1 and 
mTORC2 assemblies both contain mTOR, mLST8 (mammalian lethal with 
SEC13protein)/Gbl (G-protein b-protein subunit-like) and Deptor (EDP domain-
containing mTOR-interacting protein   However, the interaction with Raptor and 
PRAS40 denotes mTORC1 complex, whereas the presence of Rictor, mSIn1 
(mammalian stress-activated MAPK-interacting protein 1) and protor 1/2 (protein 
observed with Rictor 1/2) are representative of the TORC2 complex [146, 148].  
Little is known about the functional roles of the mTOR-associated proteins, 
however Raptor and Rictor proteins are established to function as molecular 
scaffolds needed for assembly of complexes, and PRAS40 is understood to be a 
functional suppressor of mTORC1 signaling [149].   As compared to mTORC1 
the regulation and function of mTORC2 remains unclear.  mTORC2 is 
responsible for phosphorylating AKT (Ser473), SGK1 (Ser422), and PKCα 
(Ser657) and is insensitive to rapamycin [150]. 
Downstream of mTORC1, the ribosomal protein S6K phosphorylates its 
own group of target proteins most of which are responsible for protein synthesis 
and regulation of cell size [148, 151].  The best studied target of S6K being rpS6 
(ribosomal protein S6), an integral constituent of the 40S ribosome [152].  
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Concurrently, TORC1 promotes protein synthesis by phosphorylation of 4EBP1 
which  is responsible for initiating cap-dependent translation by eiF4E (eukaryotic 
initiation factor 4E) [149].   
 
1.3  Activation of PI3K/AKT pathway in Lung Cancer 
The PI3K pathway is commonly deregulated in lung cancer as a result of  
genetic modifications affecting one or more pathway components leading to 
hyperactive PI3K signaling [153].  Activation of PI3K in cancer is generally 
brought about by oncogenic RTKs acting upstream, K-RAS, PTEN loss, or 
mutations in PI3K itself.   In lung cancers, multiple mutations are reported that 
control PI3K pathway activation, most notable are EGFR and K-RAS (discussed 
previously) and to a lesser extent by mutations in ERBB2, MET, PIK3CA, and 
PTEN.  
EGFR and cognate ligands are frequently highly expressed in NSCLC 
occurring in approximately 40-80% of tumors [154], whereas activating kinase 
domain mutations comprise approximately 10-20% of tumors [155]. Activating 
mutations present in codons 12 and 13 of GTPase domain of KRAS are 
observed in approximately 15-25% of NSCLCs [156] .  Combined, activating 
mutations affecting either EGFR and KRAS account for approximately 40-50% of 
all NSCLC cancers [157].  Crystal structures of the mutant EGFR harboring the 
TKI-sensitive L858R and G719S mutations show constitutive kinase active 
through disruptive auto inhibitory interactions [51, 158]. The constitutive signaling 
through mutant EGFR primarily activates PI3K/AKT and RAS/MAPK pathway 
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[159].   Lung cancers with mutant EGFR respond to TKI treatment with 
simultaneous abrogation of both of these survival/proliferation pathways inducing 
apoptosis and significant tumor regression.  Whereas, KRAS-active lung cancers 
depend on signaling occurring downstream of EGFR and are therefore largely de 
novo resistant to TKI therapy.   
Mutations in PI3K contribute by activating PI3K enzymatic signaling and 
therefore play an important role in tumorigenesis.  A number of somatic 
mutations have been identified in the p85 regulatory subunit that lead to 
activation of all class IA isoforms leading to unregulated cell survival and 
proliferation, however tumor specific mutations in p85 remain largely unexplored.  
With respect to the catalytic subunit of class I PI3Ks, gain-of-function oncogenic 
mutations have only been identified in the p110α (PIK3CA) isoform.  Mutations in 
PIK3CA are common to a number of cancers in particular breast and colorectal 
cancers, and account for approximately 3% of NSCLCs [160-162].   Importantly, 
NSCLC tumors having PIK3CA mutations more frequently occur concurrent with 
EGFR or K-RAS (61.8%) mutations than alone (31.2%), and were mutually 
exclusive with loss of function mutations in PTEN [163, 164]. The co-existence of 
mutant EGFR and other molecular aberrations affecting IGF-1, PTEN, and 
PIK3CA were reported to decrease sensitivity to EGFR-TKIs [155, 165]. 
Likewise, the coexistence of these molecular alterations illustrates the difficulty 
with assigning individualized single-agent targeted treatments, and further 
highlights the potential benefit for combination therapies.   
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Although activating mutations of PIK3CA occur frequently in a number of 
cancers, the loss of PTEN phosphatase still remains the most common 
mechanism of activation of PI3K pathway found in human cancers [166, 167].  
The genetic and/or epigenetic loss of PTEN phosphatase allows for uncontrolled 
PI3K kinase activity and activation of effector AKT signaling, resulting in 
unchecked proliferation and pro-survival signaling [168]. In both SCLC and 
NSCLC PTEN is rarely mutated, however considerable reduction in expression is 
common feature in lung cancers [169, 170].  Indeed, loss of PTEN expression 
and AKT overexpression confers poor prognosis in NSCLC [171].  Importantly, 
loss PTEN activity is found to contribute to erlotinib resistance in EGFR-mutant 
lung cancer by uncoupling AKT signaling from direct control of EGFR [172].  
 
1.3.1   PI3K isoforms in cancer 
Recent interest in the role of PI3K isoforms in cancer have revealed both 
unique and redundant functions related to tumorgenesis and signaling for the 
p110α and p110β isoforms, each of which represent the ubiquitous class IA 
catalytic subunits of PI3K residing in tissues of origin for most tumor types.  
p110δ and p110γ isoform expression is largely limited to cells of the immune 
system [75, 173].  The expression of p110α and p110β are essential for survival 
and each have non-redundant role with other class IA PI3Ks, as knockout mice  
demonstrate embryonic lethality at E9.5-10.5 and E3.5 for each respective 
isoform [174-176]. 
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Both p110α and p110β isoforms are thought to play differential roles in 
transformation driven by alterations in particular components of the PI3K 
pathway and therefore have tumor specific activities.  For example, tumors 
overwhelmingly receive PI3K activity through the p110α isoform when harboring 
“hotspot” mutations in PIK3CA or ERBB2 mutations such as those commonly 
found in breast and bladder cancers [177, 178].  Whereas, PTEN-null cancers 
which are common in tumors of the prostate and glioblastoma are thought to be 
mediated through p110β [179-183]. This divergence is further evident in that 
mutations affecting PIK3CA and PTEN rarely co-exist in the same cell, and 
thought to be mutually exclusive [184, 185].  Tumors with mutant PIK3CA often 
possess alterations in other components of the PI3K pathway such as RAS, and 
ERBB2/ERBB3 [178, 186]. Pharmacological and knockdown studies confirm 
signaling to AKT is directed by 110α in breast, colon, and endometrial cancers 
having co-existing mutations of PIK3CA with RAS or ERBB2/ERBB3 [187]. 
 The hotspot mutations in p110α have been found to cluster in two 
locations, the helical domain (E542K and E545K) and the in the C-lobe of kinase 
domain (H1047R) [161, 188].  The helical domain mutations prevent the 
regulatory interaction of p85 nSH2 domain by disrupting electrostatic interactions 
between helical residues and nSH2 [189].   Activation of helical domain mutants 
is no longer responsive (pY) phosphopeptides, but are still dependent on RAS to 
induce oncogenic transformation [190, 191].   The most common PIK3CA 
mutation in lung cancer, H1047R, which affects the C-lobe kinase domain 
conformation of kα4-kα5 and kα11-kα12 loops responsible for membrane 
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interaction are likely oncogenic due to increased membrane association [192].   
Consistent with this observation, the H1047R mutants do not require RAS 
activation for oncogenic transformation because the adoption of semi-activated 
confirmation of the kinase domain due to constitutive membrane localization 
[193].  
 Paradoxically, apart from p110α (PIK3CA), no other oncogenic mutations 
have been identified in any of the other class I PI3K catalytic isoforms. 
Furthermore, the transformative capacity of chicken embryo fibroblasts (CEFs) 
differs between the E545K and the H1047 PIK3CA mutants, and among the 
class IA isoforms.  Transformation required overexpression of a mutant variant 
for p110α, as compared to isoforms p110β, δ, and γ which are inherently 
oncogenic when expressed in as wild-type proteins [194].  Elegant studies using 
p110α/β chimeras to analyze the C2-iSH2 brake demonstrated that disruption of 
this inhibitory interface is partially responsible for transforming potential of wild-
type p110β and is the likely cause of high basal p110β signaling [110].  However, 
in the same study p110δ demonstrated differing characteristics in regards to the 
intact C2-iSH2 interaction, thus indicating a higher order factors are responsible 
for p110δ wild type transforming potential [110].  The disruption of this p85:p110 
inhibitory contact may also explain the failure for p110β effectively signal 
downstream of activated RTKs relative to p110α as wild-type proteins [107].   
The frequency to which PIK3CA is activated in human cancers, and the 
important role PTEN plays as the negative regulator of PI3K pathway activation, 
it could be assumed that p110α would function as the dominant isoform signaling 
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downstream of PTEN loss.  Rather, a number of recent studies put that 
assumption into question by identifying the catalytic activity of p110β as the 
essential isoform for signaling and growth of PTEN-null cancers [181-183, 195].  
This work has been validated using PTEN-null human cancer cell lines for 
prostate, brain and breast where researchers found that the both 
pharmacological inhibition using isoform-selective inhibitors of p110, and genetic 
knockdown of p110β, not p110α impaired downstream activation of AKT.  
Although controversial, a recent study has implicated p110β in specific growth of 
ERBB2-driven mammary tumors and K-RAS driven tumors [195].  Finally, p110β 
is the only class IA PI3K that signals downstream of GPCRs. This occurs via 
direct interaction with p110β catalytic subunit and Gβγ subunit, and activation 
occurs independent of the p85 regulatory subunit [196].   Although these studies 
demonstrated that p110β plays a dominant role in PI3K signaling in PTEN-
deficient tumors, it is likely that this reliance is determined by the signaling inputs 
and the genetic context.  Likewise, the contributions of GPCR-driven tumors and 
the relationship with p110β signaling remains elusive, but may hold promising 
opportunities.  It is clear that p110α and p110β demonstrate distinct and 
overlapping functions in cell signaling and tumorigenesis, continued investigation 
is needed as both pan-isoform and isoform-selective PI3K inhibitors move into 
the clinic.   
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Figure 1.2. Canonical class IA PI3K activation.  PI3K transduces signals from 
activated receptor tyrosine kinases, RAS, and GPCRs. RTKs and RAS can 
interact with multiple class IA isoforms, however each signal preferentially 
through p110α and p110δ isoforms, and to a lesser extent the p110β isoform.  
Conversely, p110β is the only isoform activated by GPCRs.  Activation of the 
PI3K pathway leads promotes cell survival, cell cycle progression and protein 
synthesis. 
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Figure 1.3.  Chemical structures of pan-class I and isoform-selective PI3K 
inhibitors.  LY294002 was the first synthesized PI3K inhibitor.  ZSTK474 is a 
pan-class I PI3K inhibitor.  A66, TGX-221 and CAL-101 are isoform-selective 
inhibitors of p110α, p110β, p110δ respectively.  
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Clinical development and therapeutic limitations of PI3K inhibitors 
Unfortunately, the majority of PI3K pathway inhibitors are currently in early 
clinical development, thus a paucity of clinical data for efficacy and toxicity.  PI3K 
inhibitors fall into 3 general categories: pan-class I PI3K, isoform-selective and 
dual PI3K/mTOR inhibitors.  The first generation of PI3K inhibitors were pan-
class I inhibitors, the natural compound wortmannin and the first synthesized 
drug LY294002 [197, 198].   These drugs demonstrated potent in vitro activities 
against PI3K signaling, however both showed considerable toxicities in animal 
studies and failed to reach clinical evaluation.  Notwithstanding, more than 15 
different agents are currently in various stages of clinical evaluation, a number of 
which utilize the functional aryl morpholine moiety present in LY294002 [199-201] 
(Figure 1.3.). Among those currently being investigated, early indications suggest 
that pan-PI3K/mTOR inhibitors may demonstrate the greatest clinical promise. 
The advantage of pan-PI3K/mTOR inhibitors is a more complete 
shutdown of the PI3K/AKT/mTOR signaling axis, which may remain active in 
some cancers capable of bypassing single isoform or pan-PI3K, AKT, and mTOR 
inhibitors related feedback activation of the pathway [202-210].  Continued 
research is needed to define the innate and acquired mechanisms of resistance 
that reconstitute PI3K signaling or activate parallel pathways during inhibitor 
treatment.   PI3K and mTOR are structurally similar, both belonging to the PI3K-
related kinases (PIKK) superfamily, and therefore similarly targeted by certain 
inhibitory compounds [82].  Preclinical in vitro studies suggest pan-PI3K/mTOR 
inhibitors have broader efficacy across a variety of genotypes as compared to 
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pan-PI3K or mTOR targeting rapamycin analogs [202, 211, 212]. NVP-BEZ235 
was the first member of the pan-PI3K/mTOR class of inhibitors to enter phase I 
clinical trials in patients with advanced solid tumors [213]. However, problems 
with increased toxicity may prove pan-PI3K/mTOR inhibitors are unsuitable for 
some genetic contexts or use in combination therapies.  Currently, we are unable 
to make the side by side comparison of clinical efficacy and toxicity between dual 
pan-PI3K/mTOR and pan-PI3K inhibitors due to lack of clinical data.  One may 
speculate that pan-PI3K inhibitors, having improved specificity relative to dual 
pan-PI3K/mTOR inhibitors, may be better suited for combination regimens with 
other targeted or chemotherapeutic agents. According to the ClinicalTrials.gov 
database, currently there a total of 19 combination trials using pan-PI3K 
inhibitors plus chemotherapy, and 9 reported for PI3K/mTOR inhibitors with 
chemotherapy.   
Isoform-selective PI3K inhibitors are in clinical development with the goal 
of targeting specific alterations in PI3K while circumventing off target toxicity 
associated with inhibiting multiple isoforms.  In particular are the development of 
p110α specific inhibitors to target tumors driven by activating PIK3CA mutations, 
and p110δ selective inhibitors for hematological malignancies.  As compared to 
pan-PI3K isoform inhibitors, isoform-selective inhibitors of PI3K have a more 
narrow activity profile among differing tumor types and will require careful patient 
selection based upon biomarkers of sensitivity [214].   The emergence of 
isoform-selective inhibitors of PI3K, and the perceived decrease in toxicity raises 
the possibility of combining these agents with other targeted inhibitors.  The use 
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of isoform-selective PI3K inhibitors with other targeted agents may offer more 
personalized therapeutic option as compared to a use with pan-PI3K inhibitors.  
Recently development and preclinical characterization of p110α selective 
inhibitors have shown differential patterns of sensitivity and resistance related to 
the genetic context.  The effects of p110α selective inhibitor BYL719 treatment in 
a large panel of cancer cell lines indicated sensitivity in tumors harboring PIK3CA 
activating mutations or amplifications or HER2 amplifications, but resistance in 
those with PTEN and BRAF alterations, and coexisting PIK3CA and KRAS 
mutations [215, 216].  Furthermore, results from phase I clinical trials with p110α 
selective inhibitors (BYL719 and GDC-0032) suggest potential benefit for these 
agents in selective tumors bearing PIK3CA mutations [217, 218].   In contrast 
with p110α selective inhibitors, recent studies suggest tumors having loss of 
function PTEN mutations are sensitive to p110β selective inhibitors.  Currently 
there are three p110β selective inhibitors in early clinical trials, AZD8186, 
GSK2636771, and SAR260301 for treatment of advanced solid tumors with 
PTEN deficiency [219-221].   
The p110δ inhibitor CAL-101 (GS-1101) is the best studied isoform-
selective PI3K inhibitor to date.  Currently in phase III trials, CAL-101 is being 
investigated for non-Hodgkin lymphoma (NHL) and chronic lymhocytic leukemia 
(CLL).   The success of CAL-101 has provided the proof of concept that isoform-
selective PI3K inhibition may be clinical relevant if acting in the appropriate 
cellular context. The p110δ isoform is primarily expressed in neutrophils, 
monocytes and lymphocytes, as well as lymphoid tissues such as the thymus, 
33 
 
lymph nodes and spleen, thus playing a central role in immune signaling through 
PI3K [222]. Targeting p110δ impairs signaling known to promote CLL migration 
and retention in bone marrow and/or lymphoid tissues, as well as directly block 
proliferation and survival of these cells.  Collectively there are three p110δ 
selective inhibitors in development, CAL-101 (GS-1101), AMG 319, and 
IC488743 (GS-9820) for treatment of lymphoid malignancies.       
 
1.4  PROJECT OVERVIEW 
The PI3K pathway is firmly established a major conduit for tumor 
proliferation and survival and is actively involved in the development and 
progression of lung cancers.  Thus, inhibitors of PI3K may be useful as a 
cytotoxic or sensitizing agents for treatment of NSCLC.  Although inhibitors of the 
pathway are currently in clinical trials, rational and targeted use of these 
compounds, alone or in combination, requires an understanding of isoform 
specific activity in context. In this body of research, the ultimate goal is to 
evaluate the therapeutic potential for isoform-selective inhibitors through detailed 
study of PI3K pathway activation, proliferation, and survival in a lung cancer 
model system. 
An overarching question to which this dissertation addresses is whether 
single-agent PI3K inhibitors can be clinically effective cancer therapeutics.  To 
date, most all clinically successful targeted therapies have been targeted 
inhibitors against tyrosine kinases, such as BCR-ABL, KIT, EGFR and ERBB2.  
The common thread among these is that target inhibition leads to the 
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downregulation of multiple signaling pathways, not just one as is the case with 
PI3K.  One major limitation of single-agent PI3K inhibitor effectiveness is the 
presence of negative feedback signaling and pathway crosstalk.   Prominent 
examples being the feedback observed with rapamycin treatment where 
mTORC1 impairment leads to reactivation of PI3K signaling through a feedback 
inhibition of IGF-1 and the extensive cross pathway regulation between 
constituents of PI3K and ERK pathways [203].   Given this, there is compelling 
rational for combining PI3K pathway inhibitors with other targeted therapies to 
improve clinical efficacy.  
To address these questions, the following testable hypothesis were 
proposed.  First, individual class IA PI3K isoforms p110α, p110β, and p110δ 
represent novel targets for therapeutic intervention in mutationally diverse 
NSCLC.  Secondly, therapeutic sensitivity and resistance to PI3K inhibition 
are mediated by pathway compensation due to presence of coexisting 
mutations, which can be overcome by combination treatment of targeted 
inhibitors.  Together this work delineates the activity of PI3K in mutationally-
defined NSCLC, discovered through the use of pan-class I and isoform-selective 
inhibitors of PI3K may direct the clinical use of PI3K inhibitors as a single-agent 
or in combination with EGFR-TKIs for select patient populations. 
 
 
 
Copyright © Chris W. Stamatkin 2014 
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CHAPTER 2 
2.1  OVERVIEW 
Lung cancer leads to the greatest morbidity and mortality of all cancer 
deaths in the United States [19]. To combat these diseases, new therapeutic 
agents and therapeutic strategies are necessary, and these strategies should 
include patient-specific therapy to minimize toxicity and cost. Targeting therapies 
to actionable mutations found in non-small cell lung carcinomas (NSCLC), such 
as mutation/amplification of epidermal growth factor receptor (EGFR) gene [223], 
activating point mutations in p110α isoform of PI3K (PIK3CA) [224], and in the 
KRAS gene [225], and deletion of the PTEN gene [172], may help achieve 
personalized treatments. Importantly, each of these genetic alterations can lead 
to increased survival signals that converge on the PI3K/AKT/mTOR cascade. 
While the PI3K pathway is a central node for control of both cell growth and cell 
proliferation in normal epithelial cells, aberrant pathway activation in lung 
tumorigenesis dysregulates cell metabolism, proliferation, apoptosis, and 
angiogenesis [226-228].   
 Many cancers depend on a hyperactive PI3K pathway. Thus, increased 
attention has been placed on development of pharmacological inhibitors of PI3K 
enzymes that are often mutated or improperly expressed in tumors [229].  
Specifically, activation of class IA PI3Ks generates plasma membrane lipid 
second messenger molecules by phosphorylating the 3’-OH position of 
phosphoatidylinositol 4,5 bisphosphate (PIP2) to produce phosphatidylinositiol-
3,4,5-trisphosphate lipid (PIP3).  While PIP3 levels are tightly regulated by the 
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cell, net pathway activation is determined by a delicate balance between the 
opposing activities of PI3K lipid kinases and 3- and 5- lipid phosphatases such as 
PTEN. Recent evidence suggests that there are specific cellular contexts and 
physiological roles for each class IA PI3K isoform: p110α (PIK3CA), p110β 
(PIK3CB), and p110δ (PIK3CD) [230, 231].  Cell-specific activities of PI3Ks 
include selective recruitment of p110 isoforms to activated receptors and second-
messenger signal diversification by interaction with various PI3K p85 isoforms.  
Additionally, activated receptor tyrosine kinases, G-protein coupled receptors, 
RAS and other small GTPases can signal through cell type-specific PI3K 
isoforms [107, 181, 182, 232-234].   Application of these data to drug discovery 
efforts revealed a role for PIK3CD inhibition for treatment of B-cell malignancies 
and autoimmune diseases [235, 236]. Finally, class IA PI3Ks may also possess 
non-catalytic activity, serving as molecular scaffolds for other signaling proteins.  
Thus, therapeutic targeting of individual PI3K class IA proteins may have clinical 
promise in solid tumors by impeding a host of PI3K functions necessary for 
cancer cell growth. 
 We hypothesized that PI3K isoform-selective inhibitors would have clinical 
value for personalized treatment of lung cancers. Herein, we describe the effects 
isoform-selective inhibition of class IA PI3K enzymes on pathway activation, 
proliferation, and viability in genetically-diverse NSCLC cell lines. Our results 
show that differences in PI3K isoform mutation status, signaling pathway 
mutations and/or amplifications, and importantly, the apparent compensatory 
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activity of PI3K isoforms may be critical considerations for personalizing cancer 
therapy using PI3K inhibitors.   
 
2.2 METHODS 
Cell Lines and Culture Conditions  
Human NSCLC cell lines obtained from American Type Culture Collection 
were A549, H460, H1650, H1975, and PC9.  The lines were frozen at low 
passage for future use and subsequently were confirmed by STR testing (Bio-
synthesis Inc, Lewisville, TX.).  All cell lines were propagated as monolayer 
cultures at 37◦C in 5% CO2 using growth media containing RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), glucose, sodium pyruvate, 
HEPES buffer and penicillin-streptomycin (Life Technologies, Grand Island, NY). 
The mutational status of each cell line 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) is found in Figure 2.1. A.   
 
Reagents 
IC488743 and CAL-101 (GS-1101) were provided by Gilead Sciences 
(Foster City, CA). A66, TGX-221, and ZSTK474 was purchased from 
Selleckchem (Houston, TX).  All inhibitors were dissolved in DMSO (Sigma 
Aldrich Corp, St. Louis, MO; BP231-100) to a stock concentration of 10mM, 
stored at -20C, and diluted to indicated final concentration in RPMI 1640 
containing FBS at time of use.  
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PI3K activity ELISA  
PI3K isoform inhibitor specificity was determined in vitro using an ELISA 
assay (Millipore, Billerica, MA; 17-493) according to manufacturer’s instructions. 
The biotinylated-PIP3 well values are set to 100. Experimental signals are 
divided by biotinylated-PIP3 then multiplied by 100 to give percent positive 
signal. IC50 values and growth curves were calculated using Graphpad Prism 
software. Figures represent percent relative to control for each drug/isoform 
concentration as indicated.  For detailed instructions, refer to the following 
document: 
http://www.millipore.com/userguides.nsf/a73664f9f981af8c852569b9005b4eee/c
a49bfd0cd79e94b852577c3007bcebd/$FILE/PI3K.pdf 
 
Cell Proliferation Assessment  
The growth inhibitory activity of each compound was tested on cells using 
the Alamar Blue viability and Trypan Blue exclusion assays [237, 238].  In the 
Alamar Blue assay, cell lines were plated at 2 x 103 cells/well in 96-well cell 
culture plate (USA Scientific, Ocala, FL; CC7682-7596), then were treated 24 hr 
later with PI3K inhibitors) for 72 hr diluted in RPMI 1640 containing 1% serum.   
For the Trypan Blue exclusion assay, cells were plated at 1 x 104 cells/well in 24-
well cell culture plate (USA Scientific, CC7682-7524). The cells were 
synchronized 24 hr later by changing media to RPMI containing 0.1% serum.  
After 24 hr serum deprivation, cells were released in RPMI containing 1% serum 
with PI3K inhibitors for 72 hr.  Cells were trypsinized, and mixed 1:1 with trypan 
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blue for visual counting of both viable and dead cells. Experimental 
concentrations from (0.3 - 30µM) of A66, TGX-221, IC488743 and CAL-101 were 
tested.  GI50 values were calculated using Graphpad Prism software. 
 
Cell Cycle and Apoptosis Analysis 
For the cell cycle study, NSCLC cell lines were plated in 60-mm dishes 
(Corning, Corning, NY; 25382-381).  After 24 hr, the cells were treated with 
ZSTK474 and IC488743 at the indicated GI75 concentrations for 24 and 48 hr. 
Following incubation, cells were trypsinized, quenched with serum, washed, 
resuspended in phosphate buffered saline (PBS), and fixed in cold 70% ethanol.    
Cell cycle distribution was assessed by staining with propidium iodide (PI) and 
evaluated by BD FACS Calibur flow cytometery. Data were analyzed with 
CellQuest software (BD Biosciences, San Jose, CA).  Analysis of apoptosis was 
performed using the same conditions as the cell cycle study, where whole-cell 
lysates were analyzed by western blot analysis for cleavage of PARP as 
described below (Cell Signaling Technology, Danvers, MA). 
 
Analysis of Protein Expression 
NSCLC cells were plated in 60-mm dishes.  After 24 hr, plating media was 
removed, and cells were synchronized in starvation media RPMI 1640 containing 
0.1% FBS for 24 hr. Concentration-dependent response experiments were 
carried out using indicated drug concentrations for 3 hr.  Similarly, time-
dependent response to drug exposure was undertaken at 1µM concentration of 
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each isoform-selective inhibitor at indicated time intervals. After drug treatment, 
cells were harvested, pelleted by centrifugation, and lysed with M-PER protein 
extraction reagent (Thermo Fisher Scientific, Waltham, MA; 78503).  
Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes for antibody exposure. Signal was elicited using chemiluminescent 
reagents (ThermoScientific/Pierce). Primary antibodies used in these 
experiments were phospho-AKT (Ser473), total AKT, phospho-ERK1/2 
(Thr302/Tyr204), total ERK1/2, phospho-S6 ribosomal protein (pS6RP) 
(Ser235/236) phospho-GSK3B (Ser9), α-tubulin, PTEN, LC3β, PARP, p85, cyclin 
D1, HSP90, Histone H3,  PI3K p110α, p110β (Cell Signaling Technology, 
Danvers, MA; 9271, 9272, 9101, 4695, 4858, 5558, 2125, 9559, 2775, 9532, 
9661, 4255, 3011, respectively) and PI3K p110δ (Santa Cruz Biotechnology, 
Santa Cruz, CA; sc-7176).  
 
Cytosolic and Nuclear Protein Extraction 
A549, PC9 and H1650 NSCLC cell lines were treated with indicated 
concentrations of agents, representing the estimated GI75 concentrations for 
IC488743 and ZSTK474.  After 48 hr exposure cells were trypsinized, quenched 
with serum, pelleted, and washed once with PBS. Nuclear and cytosolic 
compartments were separated according to NE-PER Nuclear and Cytoplasmic 
Extraction Kit protocol (ThermoScientific/Pierce, 78835).  Western blot analysis 
for cyclin D1, and controls for cytosolic and nuclear fractionation, HSP90 and 
Histone H3, were performed as described above.  
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Short Interfering RNA Knockdown (siRNA) 
Cells were plated in 6-well dishes in growth medium without antibiotics. 
After 24 hr and immediately prior to transfection, the media was changed to 
RPMI 1640 containing 1% FBS without antibiotics.  Using isoform-specific PI3K 
p110β siRNA (Smartpool-Dharmacon, Thermo Fisher Scientific, Waltham, MA; L-
003019-00) (25 nM) was pre-incubated with RNAiMAX transfection reagent (Life 
Technologies, 13778-150) then added to cells for 24 hr.  siRNA-containing media 
was replaced with RPMI 1640 containing 1% serum with or without 1µM CAL-101 
or IC488743 for 3 hr.  Cells were then harvested and extracts prepared for 
western blot analysis, as previously described in analysis of protein expression. 
 
Statistical analyses 
Cell proliferation assays were completed three times with three replicates 
per experiment (Figure 2.2., Table 2.2.). The technical replicate values were 
averaged for the three experiments and plotted, mean ± standard deviation (SD).   
ELISA experiments were completed once with technical replicate measures. IC50 
values were calculated using Graphpad Prism. 
Pharmacodynamic analysis represents three independent experiments quantified 
by densitometric analysis, pAKT (S473) normalized to tAKT, and averaged to 
reflect changes in pAKT levels (Figure 2.3.). Image J software was used for 
densitometric analysis of pAKT and tAKT levels from films. The error bars for 
each agent and cell line combination represents the SEM, n=3.   
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Cell cycle and apoptosis data represent the mean ± SD of 3 separate 
experiments, (Figure 2.6.).  Figures were generated using Graphpad Prism.  
Pearson correlation calculation was performed using GraphPad Prism software 
to compare paired GI50 values for each inhibitor quantified in serum-synchronized 
cells vs. asynchronous cells.  The r-value represents the correlation coefficient. 
 
2.3 RESULTS 
PI3K isoform expression levels or mutation status alone do not dictate 
response to PI3K inhibitors.   
We initiated the experimentation by determining the expression levels at 
the gene and protein level for class IA PI3K enzymes in a panel of NSCLC cell 
lines (Figure 2.1.).  Gene expression levels of PI3K isoforms was measured in 
NSCLC cells using Affymetrix DNA microarray technology.  Normalized 
Affymetrix signal intensity values revealed that the p110β isoform is the most 
highly expressed of the three isoforms assayed while the p110δ isoform was 
poorly expressed. Expression of important pathway members was also 
determined. PTEN demonstrated varying levels of expression among cell lines 
[239]. Even though gene expression levels vary among PI3K isoforms, levels of 
protein expression for PI3K isoforms change only modestly (Figure 2.1. B). PTEN 
expression is the most variable among pathway members assessed.  All cell 
lines show activation of AKT (S473) and varying levels of activated ERK1/2. 
Finally, mutation status for important driver mutations (EGFR, KRAS, PIK3CA, or 
PTEN) is also indicated for the cell lines utilized.  
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To assess the contribution of each class IA PI3K enzyme in lung cancer 
cells to proliferation and AKT phosphorylation, we chose pharmacological 
inhibitors of PI3K isoform activity. Inhibitors of three chemotypes previously 
shown to possess isoform-selective activity were selected: A66 (aminothiazole) 
[240]; TGX-221 (morpholinochromone) [241]; CAL-101 (quinazolinone purine) 
[242], and IC488743 [243] (Table 2.1). Briefly, A66 preferentially inhibits p110α, 
TGX-221 preferentially inhibits p110β isoform, CAL-101 and IC488743 are potent 
p110δ inhibitors, and the latter also had significant inhibitory activity against 
p110β. We used the pan-PI3K inhibitor, ZSTK474, which has low nanomolar IC50 
values for all three class IA isoforms as a control [244].  Although the IC50 values 
for these inhibitors have been independently reported [240-243], we quantified 
the kinase activity of A66, TGX-221, CAL-101 and IC488743 using a uniform 
ELISA assay (Figure 2.2.). The resulting IC50 values are consistent with those 
previously reported (Table 2.1.). 
To determine whether isoform-selective PI3K inhibitors affect NSCLC cell 
proliferation and survival, Alamar Blue and Trypan Blue exclusion assays were 
used. We tested both cell lines in asynchronous and synchronized growth 
conditions to determine if cell cycle position affected activity of the agents. First, 
asynchronously growing cells were treated for 72 hr with the pan-PI3K inhibitor, 
ZSTK474, or each of four isoform-selective inhibitors to determine the half-
maximal concentration for growth inhibition (GI50) using the Alamar Blue assay 
(Table  2.2., Figure 2.3.). In cells synchronized by serum starvation, treatment 
with PI3K inhibitors was carried out for 72 hr and assayed by Trypan Blue 
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exclusion (Appendix I: Table 2.3.). There was significant agreement between 
inhibition of asynchronous and synchronous cells as determined by match-
ranking of the inhibitors based on the calculated GI50 (r= 0.651, p= 0.001).   
In summary, pan-PI3K isoform inhibition with ZSTK474 was effective at 
blocking proliferation in all NSCLC cell lines achieving GI50 values at nanomolar 
concentrations. Treatment with isoform-selective inhibitors for p110α, p110β, and 
p110δ enzymes was largely ineffective at impairing proliferation at concentrations 
conferring isoform selectivity.  H460 and H1975 cells have the greatest sensitivity 
to the PIK3CA inhibitor, A66 (GI50 8.1µM and 1.7µM) and demonstrated the 
greatest overall responsiveness PI3K inhibition compared to other cell lines 
tested.  Conversely, PC9 and H1650 cell lines were found to be the least 
sensitive to all PI3K inhibitors tested.  In particular, PC9 cells are most resistant 
to TGX-221 and CAL-101 (GI50 >100µM), and H1650 cells are most resistant to 
A66 (GI50 >200µM). Finally, cell cycle position does not appear to alter sensitivity 
in any cell line. 
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Figure 2.1.  Expression of class IA PI3K p110 isoforms and PTEN among 
NSCLC cell lines.  (A) Relative mRNA expression of p110 isoforms and PTEN 
were measured by Affymetrix microarray analysis. NSCLC cell line mutation 
status and histopathology are indicated below as Adenocarcinoma (AD) and 
Large cell carcinoma (LC). (B) PI3K p110/p85 isoform and pathway effector 
protein expression in NSCLC cell lines was determined by immunoblotting 
analysis.  Experiments were performed using sub-confluent proliferating cells 
maintained in 10% serum containing media.  
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Figure 2.2.   Inhibitor specificity measured by Class IA PI3K isoform activity 
ELISA.  PI3K isoform inhibitor specificity was determined in vitro using an ELISA 
assay according to manufacturer’s instructions.  Points represent the average of 
replicate wells in single experiment.   IC50 values indicating drug selectivity for 
each of the PI3K isoforms p110α, β and δ are found in table below each plot 
(µM).  
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Table 2.1.  PI3K inhibitor IC50 selectivity profile.  Table indicates previously 
published biochemical selectivity’s for the class I PI3K isoforms and mTOR for 
each inhibitor tested in study (µM). 
 
 
 
 
 
 
 
 
 
 
  
IC50 (µM) p110α  p110β  p110δ  p110γ  mTOR  
Pan-PI3K inhibitor 
ZSTK474 0.017 0.053 0.046 0.049 >10 
Isoform-selective PI3K inhibitors 
A66 0.032 >12.5 >1.25 3.48 >50 
TGX-221 5 0.005 0.100 >35 >10 
CAL-101 0.82 0.56 0.002 0.089 >1 
IC488743 >20 1.2 0.005 - - 
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Table 2.2.  GI50 values of PI3K inhibitors for NSCLC cell lines.    A549, H460, 
H1975, PC9, and H1650 were treated with increasing concentrations of PI3K 
inhibitors: ZSTK474, A66, TGX-221, IC488743, and CAL-101 for 72 hr  (0.03 - 
100μM). Cell proliferation was determined by Alamar Blue viability assay.  Non-
linear curve fitting and GI50 values were generated using Graphpad Prism. 
 
 
 
 
 
 
 
GI50 (µM) A549 H460  H1975  PC9  H1650  
Pan-PI3K inhibitor 
ZSTK474 0.33 0.15 0.21 0.40 0.69 
Isoform-selective PI3K inhibitors 
A66 15.64 8.10 1.74 23.31 >200 
TGX-221 24.19 26.78 21.88 120.5 50.14 
CAL-101 22.09 10.66 10.85 131.6 62.10 
IC488743 22.80 17.45 14.28 32.15 24.45 
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Figure 2.3.  Growth inhibition activity PI3K inhibitors against a panel of 5 
NSCLC cell lines.  A549, H460, H1975, PC9, and H1650 were treated with 
increasing concentrations of PI3K inhibitors: ZSTK474, A66, TGX-221, 
IC488743, and CAL-101 for 72 hr (0.03 - 100μM). Cell proliferation was 
determined by Alamar Blue viability assay.  Each experiment was performed with 
triplicate cultures, for 3 independent experiments (n=3).  Error bars represent 
standard deviation (SD).  Experimental results were normalized to 24 hr plated 
cells and divided by untreated control to determine (% growth relative to control).   
Non-linear curve fitting and GI50 values were generated using Graphpad Prism. 
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Inhibition of PI3K/AKT blocks survival signals necessary for proliferation 
 To assess whether the lack of proliferative response of the cell lines to 
isoform-selective inhibitors of the PI3K enzymes was due to inadequate target 
inhibition, we tested AKT activation over a range of inhibitor concentrations by 
western analysis of serine 473 phosphorylation after 3 hr of treatment. The ratio 
of pAKT/tAKT was determined by densitometric evaluation of the immunoblots 
and is plotted for each cell line and isoform-selective inhibitor at indicated 
concentrations (Figure 2.4.).  
Consistent with the proliferation assays, H1975 and H460 cell lines 
demonstrate the greatest reduction of pAKT at nanomolar concentrations of A66 
while H1650 demonstrated only minor reduction in pAKT even at high 
concentrations (Figure 2.4. A). Treatment with the p110β inhibitor, TGX-221, had 
little effect on AKT phosphorylation in all cell lines except for the H1650 cells 
(Figure 2.4. B). H1650 cells demonstrated nearly 75% reduction in pAKT at 
nanomolar levels of TGX-221. Treatment with the p110δ inhibitors (CAL-101 and 
IC488743) reduced AKT phosphorylation below 50% at the highest 
concentrations used for most cell lines (Figure 2.4. C and 2.4. D).  As compared 
to the isoform-selective inhibition, treatment with the pan-class I PI3K ZSTK474 
was followed by complete loss of pAKT at all concentrations except for at 0.1µM, 
whereby we achieve >50% decrease in all cell lines tested (Figure 2.5.).  We did 
not observe any change in pERK1/2 phosphorylation in response to 3 hr 
ZSTK474 treatment.  
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Recent studies identify the catalytic activity of p110β as the essential 
isoform for signaling and growth of PTEN-null cancers, we sought to further 
validate these findings by testing the isoform-selective inhibitors utilized in this 
study in the PTEN-null prostate cancer cell line, PC3 (Figure 2.6.).   We note 
activated PI3K/AKT signaling and basal expression levels of class IA PI3K 
isoforms at similar levels to those found in NSCLC cell lines.  As indicated by the 
pharmacodynamic and proliferative responses to isoform-selective inhibitor 
treatment, PC3 cells demonstrated the greatest sensitivity to the p110β inhibitor, 
TGX-221, and were least responsive to the p110α inhibition.  Treatment with the 
p110δ inhibitors were able to diminish pAKT signaling, but had limited effects on 
proliferation.  
 To determine the duration of inhibition of effector molecule (pAKT and 
pS6RP) phosphorylation, a time course was performed with 1μM of each inhibitor 
on three NSCLC lines (A549, PC9, H1650) (Figure 2.7.). At this concentration 
(1μM), each compound is predicted to be largely on-target, having a minor 
impact on other PI3K isoforms. The duration of activity was consistent with both 
the proliferation and concentration-dependent treatment assays. Specifically, the 
effect of each inhibitor against A549 cells was sustained over time, as measured 
by reduction in phosphorylation of AKT and S6. The PC9 cells displayed minimal 
response to each agent demonstrated by uninterrupted pAKT levels, except for 
A66. However, like the other cell lines, pS6 was reduced over time with each 
inhibitor relative to untreated cells. Like PC9 cells, H1650 cells also 
demonstrated sustained responses to each agent as measured by absence of S6 
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phosphorylation. However, A66 is ineffective at reducing pAKT levels, unlike 
other agents relative to the untreated control. The accumulated data suggest that 
loss of a single PI3K class I isoform might be compensated by remaining 
isoforms. To test this hypothesis, we undertook an experiment to couple gene 
depletion with pharmacological treatment. 
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Figure 2.4.  Pharmacodynamic responses to PI3K isoform-selective 
inhibition.  The relative levels of phosphorylated AKT in NSCLC cell lines (A549, 
H460, H1975, PC9, H1650) treated with increasing concentrations (0.1-10μM) of 
PI3K inhibitors (A) A66 (B) TGX-221 (C) CAL-101 and (D) IC488743.  Cells were 
synchronized by serum-starvation for 24 hr prior to release in RPMI 1640 media 
containing 1% serum with or without drug for 3 hr. Cell lysates were collected for 
immunoblotting analysis with pAKT (S473) and tAKT antibodies. α-tubulin serves 
as the normalization control.  ImageJ software was used for densitometric 
analysis of pAKT and tAKT levels. Three independent experiments were 
quantified, pAKT (S473) was normalized to tAKT, and data were averaged to 
reflect relative changes in pAKT (S473) activation.  Error bars represent mean ± 
SEM. PIK3CA mutant cell lines are indicated. 
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Figure 2.5.  Pharmacodynamic responses to pan-class I PI3K inhibitor 
ZSTK474.  The relative levels of phosphorylated AKT in NSCLC cell lines (A549, 
PC9, and H1650) treated with increasing concentrations of ZSTK474 (0.1-10μM).  
Cells were synchronized by serum-starvation for 24 hr prior to release in RPMI 
1640 media containing 1% serum with or without drug for 3 hr. Cell lysates were 
collected for immunoblotting analysis with pAKT (S473), tAKT, pERK1/2, tERK 
and α-tubulin antibodies. 
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Figure 2.6.  Basal class IA PI3K expression, proliferation and 
pharmacodynamic responses to isoform-selective inhibitors in PTEN-null 
prostate cancer cell line PC3.  (A) Class IA p110 isoform and pathway effector 
protein expression as determined by immunoblotting analysis.  Proliferating cells 
in 10% serum containing RPMI were harvested 24 hr after plating. (B) PC3 cells 
were treated with increasing concentrations of PI3K inhibitors; A66, TGX-221, 
IC488743, and CAL-101 for 72 hr (0.03 - 30μM) and proliferation was determined 
by Alamar Blue viability assay as described previously. (C) The relative levels of 
phosphorylated AKT after treatment with increasing concentrations of A66, TGX-
221, CAL-101 and IC488743.  Cells were synchronized by serum-starvation for 
24 hr prior to release in RPMI 1640 media containing 1% serum with or without 
drug for 3 hr. Cell lysates were collected for immunoblotting analysis with pAKT 
(S473), tAKT, and α-tubulin antibodies. 
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Figure 2.7.  Isoform-selective PI3K inhibitor treatment demonstrates 
sustained time-dependent inhibition of PI3K signaling.  A549, PC9 and 
H1650 cells were treated with 1μM isoform-selective inhibitors in RPMI 1640 
containing 1% serum for regular time intervals of 1, 6, 12, 24, 48, 72 hr after drug 
addition.  Untreated controls were tested using identical conditions but without 
drug addition.  Samples were collected at each time point for immunoblotting with 
indicated antibodies as described above. α-tubulin serves as the normalization 
control. 
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siRNA knockdown of p110β does not phenocopy effects observed with 
PIK3CB and D inhibition.    
 The previous experiments provided evidence that inhibition of proliferation 
and loss of AKT signaling manifested at concentrations of each inhibitor that 
exceeded selectivity for a single isoform. Only the pan-inhibitor, ZSTK474, was 
effective at inhibiting proliferation at sub-micromolar concentrations, suggesting 
that in most cells PI3K activity was necessary. Further, the cell lines with 
activating PIK3CA mutations (H460 and H1975) were the most sensitive to A66, 
as previously described in the breast cancer literature [218, 245, 246].  We 
hypothesized that PI3K isoforms may be able to compensate for one another. 
We tested this hypothesis on the cells least sensitive to PIK3CA pharmacological 
inhibition (A549, PC9, H1650).  Expression of p110β was ablated using short-
interfering RNA (siRNA) then cells were treated with either CAL-101 or IC488743 
for 3 hr at 1µM concentration.   
Silencing of p110β isoform reduced expression of p110β in A549 by 80%, 
in PC9 by 55%, and in H1650 by 61%, as measured by densitometry (Figure 2.8. 
A). However, partial ablation of the p110β isoform alone did not significantly 
reduce phosphorylation of AKT at S473 compared with IC488743 or CAL-101 
treatment alone in all cells, suggesting that p110α and p110δ isoforms, or 
residual p110β, can compensate for the genetic loss of p110β.  Importantly, the 
observed decrease in pAKT after p110β ablation with CAL-101 treatment was not 
superior to treatment with CAL-101 alone.  Similarly, treatment of p110β-depleted 
cells with IC488743 prompted a minor decrease pAKT levels compared with the 
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either p110β-depletion or IC488743 treatment, suggesting that PIK3CA is 
responsible for the remaining activity (Figure 2.8. B).   
Interestingly, pERK1/2 signaling was reduced in H1650 cells in the p110β 
knockdown cells for all conditions (plus or minus CAL-101 or IC488743), but not 
the other lines (Figure 2.8. A). Densitometric analysis of pERK1/2 showed 
reduction of signal of nearly 50%, suggesting that one or both isoforms play a 
role in RAS/MAPK signaling in H1650 cells which may be independent of the 
phosphorylation of AKT.  These data suggest that both the AKT and RAS/MAPK 
signaling cascades may be linked by multiple independent PI3K isoforms, and 
functionally these may have kinase independent roles such as a molecular 
scaffold or adaptor protein. 
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Figure 2.8.  Functional redundancies among class IA isoforms maintain 
PI3K pathway activation after siRNA-mediated ablation PIK3CB and 
pharmacological inhibition PIK3CD.  (A) A549, PC9, and H1650 cells were 
transiently-transfected with siRNA specific for p110β for 24 hr (25nM), then 
treated with p110δ inhibitors CAL-101 or IC488743 (1µM) for 3 hours before 
harvesting.  Cell lysates were prepared for immunoblotting with indicated 
antibodies. (B) Densitometric analysis of pAKT (S473) levels normalized to tAKT 
expression levels. 
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Treatment with IC488743 or ZSTK474 promotes cell cycle arrest in G1 but 
not apoptosis NSCLC cells  
 Inhibition of p110β and p110δ isoforms by genetic and/or pharmacological 
treatment reduced cell proliferation and inhibited PI3K signaling in A549, PC9, 
and H1650 NSCLC lines better than isoform-specific inhibitors alone. We sought 
to understand if reduced proliferation was due to cell cycle arrest or induction of 
apoptosis, given that the potential consequences on normal and tumor cells. 
To identify the cause of reduction in proliferation, we first investigated the 
cell cycle profile of cells treated with the IC488743 as compared to the pan-
isoform inhibitor ZSTK474 at the individual GI75 concentrations for cell lines 
A549, PC9, and H1650. We chose to assess the compounds at the GI75 because 
this is the relative concentration where a proliferative phenotype was observed 
with IC488743. Importantly, when evaluating differences in sensitivity between 
the two inhibitors, ZSTK474 was on average >50-fold more potent than IC488743 
(1.3µM vs 73.3µM) among the three cell lines.  After 24 hr of treatment, both 
compounds led to significant accumulation in G1 phase for each cell line with 
concomitant loss in the S phase compartment (Figure 2.9. A).  At 48 hr, we 
observed a sustained arrest in G1 in A549 and H1650, however PC9 cells appear 
to exit G1 and re-enter into cell cycle.  Additionally, at both 24 and 48 hr we 
detected no change in the % sub-G1 population suggesting apoptosis was not 
being induced by inhibitor treatments for all cell lines tested (Figure 2.6. B).   
 Using identical conditions as outlined above, we also assessed pathway 
and apoptotic signaling at 24 and 48 hr after treatment with IC488743 and 
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ZSTK474.   As expected, both drugs inhibited phosphorylation of AKT S473 at 
each time interval. We also observed re-activation of pERK1/2 signaling in the 
PC9 and H1650 cells (Figure 2.9. C).  The increase in pERK signaling in 
response to treatment was most pronounced in response to ZSTK474 in the 
EGFR mutant cell lines H1650 and PC9, with only a minor increase observed in 
KRAS-active A549 cells.  We also evaluated cleaved PARP as an apoptotic 
signaling molecule.   We observed no change in cleaved PARP levels with 
treatment which is consistent with our inability to detect significant changes in 
sub-G1 fraction after treatment (Figures 2.9. B and 2.9. C).  
To characterize treatment effects on cell cycle progression, we evaluated 
nuclear and cytosolic levels of cyclin D1 after 48 hr treatments (Figure 2.9. D). 
Cyclin D1 should be extruded from the nucleus of cycling cells. After 48 hr, cyclin 
D1 accumulated in the cytosol with treatment of IC488743 or ZSTK474 relative to 
the controls in A549 and H1650 cells. However, in PC9 cells we observed the 
presence of nuclear cyclin D1 in drug treated samples, suggesting progression 
into the cell cycle. Fractionation of the nuclear and cytosolic compartments was 
confirmed by histone H3 and HSP90 localization.  
 From these data, only pan-PI3K inhibition or an isoform-selective inhibitor 
utilized at non-selective concentrations can diminish PI3K/AKT signaling 
sufficient block proliferation while not inducing apoptosis.  However, we note G1 
blockade may be temporary, and taken together with apoptotic failure are likely 
the result of compensatory mechanisms that increase pERK signaling to escape 
PI3K/AKT inhibition.  
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Figure 2.9.    IC488743 and ZSTK474 treatment alters G1 cell cycle 
progression without inducing apoptosis. (A) Control, IC488743 and ZSTK474 
treatment at GI75 concentrations for A549 (IC 65µM and Z 1µM), PC9 (IC 100µM, 
Z 1.3µM), and H1650 (IC 55µM, Z 1.6µM) cells were assessed for relative cell 
cycle distributions by propidium iodide (PI) staining of DNA following 24 hr and 
48 hr of treatment.  Mean percentages of cells in G0/G1, S, and G2/M are 
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indicated. Error bars represent standard deviation, (n=3) and Student t test 
showed significant difference (*p<0.05). (B) Control, IC488743, and ZSTK474 
treated A549, PC9 and H1650 cells were analyzed for % sub-G1 population 
indicating apoptosis.  Mean percentages of sub-G1 cells are displayed. Error bars 
represent standard deviation, (n=3). (C) Markers for pathway activation and 
apoptosis assayed in A549, PC9, and H1650 cells treated at GI75 concentrations 
of IC488743 (IC) or ZSTK474 (Z) for 24 and 48 hr then harvested for western blot 
analysis. (D) Cells treated for 48 hr with GI75 concentrations of IC488743 or 
ZSTK474 were subjected nuclear and cytosolic fractionation then western blot 
analysis to determine the sub cellular localization of G1 to S-phase regulatory 
protein cyclin D1. 
 
2.4. DISCUSSION 
 Lung cancer is a disease characterized by extensive genomic changes 
that unfortunately lead to millions of deaths worldwide each year because 
patients do not achieve a sustained response to therapy [247].  Only recently 
have actionable mutations and mutated signaling pathways been identified and 
targeted therapeutically [248-251]. Our interests converge on the 
PI3K/AKT/mTOR signaling axis because it represents one of the most commonly 
activated pathways in cancer for which few targeted therapies have resulted in 
clinical use in lung cancer [252].   
 In lung cancers, mutations have been reported in multiple genes that 
control PI3K/AKT pathway activation, including EGFR, KRAS, HER3 and BRAF 
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[49, 159, 186], even though few adenocarcinomas of the lung demonstrate 
mutations in PIK3CA [163].  Together, these observations make the effector 
molecules of the PI3K pathway alluring targets for cancer therapy.  First 
generation PI3K inhibitors targeted all class I PI3K isoforms, but were not 
suitable for clinical use due largely to toxicity and poor bioavailability [253, 254].  
Although class IA PI3K isoforms possess similar protein structure, control of 
expression, and regulation of activity, recent literature reports non-redundant 
cellular functions that appear to be isoform specific [108, 255-260].  Importantly, 
to our knowledge, PI3K isoform-specific activities have not been dissected in 
lung cancers. Therefore, we chose to investigate the intersection of 
therapeutically-actionable mutations and deregulated activities of the PI3K/AKT 
signaling cascade in NSCLC cell lines.  
 We investigated the activity of a panel of PI3K inhibitory compounds in 
vitro and in cell lines. The IC50 values PI3K isoform specificity and selectivity 
have been previously published and further validated by this laboratory. Using 
these compounds as tools, we intended to evaluate the activity of each 
compound for inhibition of growth and/or cell killing in a panel of NSCLC cells 
and to independently assess the necessity of each PI3K class IA enzymes in 
NSCLC.  
 We investigated anti-proliferative responses using a range of drug 
concentrations overlapping our in vitro estimation of IC50 for each isoform. We 
found that several compounds have anti-proliferative activity against the cell lines 
tested at micromolar concentrations.  Importantly, we found that cell lines 
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containing mutated PIK3CA were most sensitive to A66. Notably, H460 bears an 
activating mutation in PIK3CA (E545K) as does H1975 (G188D) which 
apparently sensitizes the cells to A66 (GI50 8.1µM vs 1.59µM, respectively).   
CAL-101 (GS-1101) is a small molecule inhibitor of p110δ isoform that has been 
demonstrated to having promising activity against chronic lymphocytic leukemia 
(CLL) [173, 222, 236].   We found that CAL-101 has similar anti-proliferative 
activity as the other p110δ inhibitor tested, IC488743, each demonstrating best 
activity in H1975 and H460 cell lines.  Although CAL-101 and IC488743 elicited 
similar anti-proliferative profiles they differed most in the EGFR mutant lines PC9 
and H1650.  It is important to note that the GI50 values for even the most 
sensitive cell lines were well above those estimated IC50 values for isoform 
selectivity, and pharmacologically unachievable.  However the data also suggest 
that at micromolar concentrations we may be achieving dual inhibition of p110β 
and p110δ while sparing p110α, resulting in diminished cellular proliferation for 
several cells of multiple genotypes.  Having similar potency for individual class IA 
isoforms as the isoform-selective inhibitors, the pan-PI3K inhibitor ZSTK474 was 
far more effective at blocking proliferation than any of the isoform-selective 
inhibitors tested having GI50 in nanomolar range for all NSCLC cell lines. 
The dose-dependent pharmacodynamic experiments largely mirror the 
proliferation results. Pan-PI3K inhibition with ZSTK474 completely abrogated 
pAKT signaling at 0.5µM and >50% at 0.1µM for A549, H1650 and PC9 cell lines 
(Figure 2.5.).   For isoform-selective inhibitors, impaired PI3K/AKT pathway 
signaling was observed at micromolar concentrations, and elicited an anti-
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proliferative response in most cases. Whereas, treatment at concentrations 
suitable for on target single isoform selectivity had little effect on proliferative 
signaling with the exception of A66 in PIK3CA active H1975 and possibly H460.  
A noteworthy counter example was identified in the PTEN-null prostate cancer 
cell line PC3, where we found selective p110β inhibition with TGX-221 effective 
at blocking proliferation and pathway activation relative to p110α, and 
p110δ selective inhibitors (Figure 2.6.).  However, among the NSCLC cell lines, 
TGX-221, CAL-101 and IC488743, to achieve proliferative control these drugs 
are acting like weak pan-class IA PI3K inhibitors, largely inhibiting only p110β 
and p110δ, and off-target activity on p110α at higher concentrations.  Consistent 
with this experiment, time-dependent inhibition of PI3K/AKT signaling was 
achieved with partial off-target activity that had differential effects that were 
sustained among the NSCLC cell lines.  From these observations it is evident 
that PC9 cells are resistant to targeting p110β and p110δ isoforms, whereas 
H1650 cells are resistant to targeting p110α.   
Together, these data suggest that there may be inherent resistance 
mechanisms in place in these cells such that isoform-selective inhibition of 
individual PI3Ks has minimal impact on intrinsic cell proliferative and survival 
signals.  
Interestingly, in the preclinical development of CAL-101, drug 
concentrations of 5-10µM were needed to achieve cytotoxic activity which is at 
least 1000x more than the predicted IC50 for p110δ, likely inhibiting both p110β 
and p110γ PI3K isoforms.   Furthermore, clinical exposure to CAL-101 is greater 
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than 2µM at lowest doses, suggesting that partial inhibition of other PI3K 
isoforms such as p110β may contribute in part to clinical cytotoxic effects 
observed in patients [242, 243, 261, 262].  Thus, therapeutic resistance to PI3K 
isoform-specific inhibition might involve one or more of the following 
mechanisms: compensation by other PI3K enzymes, compensatory signaling 
from components within PI3K/AKT pathway and/or elements from other 
oncogenic pathways, or over-expression of efflux transporters.   
We chose to investigate the possibility of compensating PI3K enzymes 
with respect to resistance to the PIK3CD inhibitors, CAL-101 and IC488743, 
each of which possess a different selectivity profile for PIK3CA, PIK3CB and 
PIK3CD.  Using siRNA-mediated knockdown of p110β, we tested the activity of 
CAL-101 and IC488743 in three cell lines each having variable sensitivity to 
either drug. From this experiment, it seems likely that ablation of two of the three 
enzymes of interest (PI3KA/B/D) is necessary to eliminate the majority of the 
pAKT activity, thought to mediate cell growth and survival. 
 Given that inhibition of multiple PI3K enzymes results in reduced 
proliferation, we also investigated the mechanism by which proliferation is halted 
in the presence of IC488743 and ZSTK474. The concentrations needed to 
achieve GI75 were significantly lower for the pan-PI3K inhibitor (1 - 1.6µM) as 
compared to IC488743 (55 - 100µM), further suggesting that pan-isoform 
blockade may be therapeutically necessary to negate compensatory PI3K 
signaling from other class IA isoforms that allow for continued proliferation.  Our 
results indicate that both inhibitors impaired PI3K/AKT pathway signaling leading 
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to G1 cell cycle arrest, which corresponded with increased cytosolic sequestration 
of cyclin D1.   Despite having potent effects on proliferation, there was no 
observable induction of apoptosis for either drug suggesting that targeted 
inhibition of only the PI3K pathway is insufficient to induce apoptosis in NSCLC 
cells bearing similar genetic aberrations.  In line with this, we observed a 
reciprocal increase in pERK after treatment with IC488743 and ZSTK474, 
indicating these cells may be exploiting the extensive pathway cross-talk and 
feedback mechanisms between PI3K/AKT and RAS/MAPK pathways that allow 
for cell cycle re-entry and escape from apoptosis.  Interestingly, this increase in 
pERK is not observed in our early 3 hr concentration responses to ZSTK474 
treatment at similar concentrations.  However, others have shown time 
dependent feedback activation in response to PI3K inhibition often occur through 
FOX3A-mediated transcriptional upregulation of ERBB family receptors such as 
HER2 and HER3 leading to increased pERK signaling [263].  
 
2.5 CONCLUSIONS  
In summary, we hypothesized that isoform-selective inhibition of PI3K 
class IA enzymes was a rational choice for lung cancer patient therapy.  
Importantly, we found that PIK3CA mutated cells responded to p110α inhibition.  
Inhibition of both p110β/δ was more effective than inhibition of individual p110β 
and p110δ isoforms alone, however none of these appear to have clinical 
relevancy among the NSCLC tumor subtypes we tested.  Overall, our findings 
provide evidence that redundancy among class IA isoforms contributes to drug 
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resistance, and that pan-class I PI3K inhibitors may hold greater therapeutic 
promise.   Given the challenges for identifying effective treatment of lung cancer 
and the need to overcome various forms of therapeutic resistance, the most 
effective use of PI3K inhibitors may ultimately be in combination with other 
targeted or cytotoxic therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Chris W. Stamatkin 2014 
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CHAPTER 3  
3.1.1 OVERVIEW 
The deregulated activation the PI3K pathway is a hallmark in human 
cancer, thus making PI3K a logical target for therapeutic exploitation.  New 
inhibitors of the PI3K pathway having improved potency and fewer side effects 
compared to first generation drugs [201].  Of these, there has been increasing 
interest those inhibitors having selectivity for individual PI3K isoforms.  Our lab as 
well as others report that class IA PI3K isoforms have both dependent and 
redundant activities that is partially determined by the genetic context [231]. 
Accrued knowledge from these studies suggests that p110α responds 
preferentially to activated receptor tyrosine kinases (TKIs) whereas, p110β is the 
dominant isoform in tumors having phosphatase and tensin homolog (PTEN) 
loss-of-function mutations [99, 173, 174, 219-221].  Our studies outlined in 
Chapter 2 characterized and compared the activity of class IA isoform-selective 
inhibitors with that of a pan-class I PI3K inhibitor and found that likely 
compensatory signaling among the isoforms reduced overall sensitivity to the 
inhibitors despite genetic drivers, thus limiting the therapeutic promise for these 
drugs.  
The implementation of molecular-based targeted therapies should not be a 
“one size fits all” approach. The mutational heterogeneity of lung cancers have 
made difficult single-agent targeted therapeutics as compared to traditional 
chemotherapies.  The inhibition of a single target or pathway essential for tumor 
proliferation is likely a temporary effect and does not produce sustained growth 
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arrest.  Prominent examples are found for inhibitors targeting EGFR, estrogen 
receptor (ER), and androgen receptor (AR) [38, 264, 265].  The complexity of 
tumor signaling networks, particularly in advanced tumors, which often have 
multiple molecular aberrations and context-specific pathway crosstalk, that 
ultimately prevent or circumvent the therapeutic blockade.   Therefore, adopting a 
strategy to achieve robust lasting therapeutic control of a cancer may require 
rational combinations of targeted anti-cancer agents.   The use of combined 
targeted therapies may serve to impair compensatory mechanisms and 
overcome resistance to therapy, and will require a better understanding of the 
complex signaling in context with molecular drivers of disease to identify valuable 
drug combinations. 
 
3.1.2 INTRODUCTION 
In adenocarcinomas of the lung, activating mutations in EGFR and KRAS 
comprise approximately 40% of genetic alterations.  EML4ALK translocations, 
loss/gain of function of BRAF, PIK3CA, AKT1 and MEK comprise another 10-
15% of cases [36].  A unifying theme among all of these alterations is that they 
interact either directly or indirectly with the PI3K pathway signaling.  Importantly, 
targeted inhibition of the epidermal growth factor receptor (EGFR) can be an 
important target for treatment of advanced non-small cell lung cancer (NSCLC) 
[249, 266].  These drugs are safe, maintain a good toxicity profile and are well 
tolerated at high doses [267]. Small molecule inhibitors that block the tyrosine 
kinase domain of EGFR have been approved for treatment of locally advanced or 
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metastatic NSCLC as a second- or third-line therapy [266].  Although, EGFR-
TKIs are approved as second-line treatment for advanced NSCLC, nearly 50% of 
patients are unable to obtain second-line treatment (non-platinum single-agent 
cytotoxic) due to the rapid decline of their clinical condition [268]. This represents 
key clinical end-point, especially for patients with aggressive tumors, as they 
need to be treated with drugs that in a second-line setting that demonstrate 
prolonged survival and preserve quality of life [269].  Divergent clinical responses 
to EGFR-TKI treatments have been associated with EGFR mutations and KRAS 
mutations.  Patients harboring EGFR mutations in exons 19 and 21 are sensitive 
to TKI, whereas presence of PTEN or KRAS mutations define innate resistance 
to TKI therapy. However, most who initially benefit from EGFR-TKI treatment  
eventually experience tumor regrowth after 12 months of progression free 
disease [270].  Approximately 75% of resistance on therapy are attributable to 
either the T790M mutations of EGFR or the amplification of MET oncogene. 
Each of these can lead to reactivation of PI3K survival signaling [43-45].  
Unlike EGFR mutant tumors, there are no current targeted therapeutic 
options for KRAS-active cancers. Activating mutations in KRAS result in 
defective GTPase activity leading to constitutive activation of multiple pathways 
responsible for cell growth and survival such as PI3K/AKT and RAF/MEK/ERK 
pathways [271].  Efforts to directly target KRAS have proven unsuccessful to 
date. However, other routes currently being investigated are to target the 
downstream effectors of RAS such as RAF, MEK, and PI3K. Although KRAS-
active cancers are generally thought to be unresponsive to EGFR-TKI therapy, 
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there is also a more complex model to consider.  Others have demonstrated that 
genotypically heterogeneous subpopulations of tumors are common [272].  
Assuming the TKI-sensitive EGFR mutant subpopulations are killed by the 
targeted therapy, the growth and maintenance of the remaining non-EGFR 
mutant cells are unaffected manifesting as therapeutic resistance.  In the 
SATURN trial, a large phase III trial having 889 randomized patients having not 
progressed after first-line chemotherapy, received erlotinib or placebo as a 
maintenance treatment [273].  Of these, 493 (55.4%) were analyzed for KRAS 
mutations. The study found that, irrespective of KRAS status, patients treated 
with erlotinib had longer progression free survival (PFS), with a modest but not 
statistically significant in improvement in the KRAS mutant population. Meaning 
that in patients harboring KRAS mutations that do not respond to EGFR-TKIs, a 
minimal survival effect may occur.  Although several studies do identify a higher 
prevalence of clinical  responders among KRAS wild-type as compared to KRAS 
mutant, diagnostic KRAS testing is not recommended for precluding an EGFR-
TKI therapy to any NSCLC patients [274-276].  One must also consider the 
possibility that wild-type EGFR may still play a role in modulating growth survival 
signaling in KRAS-active cancers.   
As summarized above, KRAS-active cancers and other therapy resistant 
subpopulations may receive some, albeit minor clinical benefit from targeted 
EGFR therapy overall.  Consequently, any undiagnosed mutant tumor 
subpopulations harboring PTEN or KRAS mutations may negatively impact tumor 
responses to single-agent EGFR directed therapies leading to tumor regrowth.   
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Studies have shown tumor subpopulations harboring KRAS mutations in lung 
and colon cancers to persist at higher levels relative to normal tissue, however 
remaining undetectable by standard DNA sequencing techniques [277, 278]. 
Furthermore, PTEN and KRAS mutation status often differ between primary and 
metastatic tumors [279, 280].  This knowledge provides rationale for combining 
therapies that impair oncogenic pathways deregulated by PTEN and KRAS 
mutations (PI3K inhibitor), with those that inhibit EGFR signaling (EGFR-TKI). 
 Therefore, we propose an accelerated therapeutic strategy intended to 
prolong survival of those with advanced NSCLC after failure to progress on first-
line chemotherapy by treating with EGFR-TKI in combination with a pan-PI3K 
inhibitor as maintenance therapy subsequent to receiving first-line chemotherapy.  
We hypothesize that the combined treatment with an EGFR-TKI and pan-PI3K 
inhibitor will have clinical value, interacting synergistically to sensitize NSCLC 
cancers innately resistant to EGFR targeted therapy.  Our study found that 
despite being inherently resistant to EGFR-TKI inhibitors, tumors harboring 
KRAS mutations or defective PTEN are sensitized to EGFR therapy when 
combined with PI3K inhibition to arrest cell proliferation.   
 
3.2. METHODS 
Cell Lines and Culture Conditions  
Human NSCLC cell lines obtained from American Type Culture Collection 
were A549, H460, and H1650.  The lines were frozen at low passage for future 
use and subsequently were confirmed by STR testing (Bio-synthesis Inc, 
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Lewisville, TX.).  All cell lines were propagated as monolayer cultures at 37◦C in 
5% CO2 using growth media containing RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), glucose, sodium pyruvate, HEPES buffer and penicillin-
streptomycin (Life Technologies, Grand Island, NY).  
 
Reagents 
The inhibitors erlotinib (EGFR-TKI) and ZSTK474 (pan-PI3K) were 
purchased from Selleckchem (Houston, TX).  All inhibitors were dissolved in 
DMSO (Sigma Aldrich Corp, St. Louis, MO; BP231-100) to a stock concentration 
of 10mM, stored at -20C, and diluted to indicated final concentration in RPMI 
1640 containing 1% FBS at time of use.  
 
Cell Proliferation Assessment  
The growth inhibitory activity of each compound was tested on cells using 
the Alamar Blue viability assay [237, 238].   Cells were plated at 2 x 103 cells/well 
in 96-well cell culture plate (USA Scientific, Ocala, FL; CC7682-7596).  After 
adherence, cells were treated 24 hr later with treated with indicated combinations 
of erlotinib and ZSTK474 for 72 hr diluted in RPMI 1640 containing 1% serum.  
Dose-response curves and GI50 values were calculated using Graphpad Prism 
software. 
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Statistical analyses 
Cell proliferation assays were completed three times with a minimum of 2 
replicates per experiment.  The technical replicate values were averaged for the 
three experiments and plotted, mean ± standard deviation (SD).  CompuSyn 
software was used to evaluate drug combination median effects and combination 
indices (CI).  CompuSyn algorithm simulating drug interactions utilize Chou-
Talalay method, where additive effect (CI = 1), synergism (CI > 1), and 
antagonism (CI > 1) [281].   
 
3.3. RESULTS 
Combined EGFR-TKI and pan-PI3K inhibitor act synergistically to impair 
proliferation of KRAS-active NSCLC  
We investigated the growth inhibitory activity of the EGFR-TKI, erlotinib, 
and the pan-PI3K inhibitor, ZSTK474, as measured in the NSCLC cell lines A549 
and H460 by Alamar Blue assay (Figure 3.1.)  We found that both A549 and 
H460 were similarly insensitive to single-agent exposure to erlotinib, reaching 
50% growth inhibition at concentrations >3µM.  The pan-PI3K inhibitor was 
markedly more potent, achieving half maximal growth inhibitory concentration in 
the nanomolar range.   
Studies were then performed to determine the effect of combined EGFR-
TKI and pan-PI3K inhibitor treatment on cell proliferation over 72 hr.  Each 
inhibitor combination was tested at concentrations spanning GI50 values. We 
found that the combinations of erlotinib and ZSTK474 were more growth 
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inhibitory than either compound alone. Although similar, H460 cells demonstrated 
greater growth inhibition in response to the drug combinations.  Growth inhibition 
was evauated by median effect analysis (CompuSyn, Memorial Sloan-Kettering 
Cancer Center and MIT) to determine if the improved growth inhibitory activity of 
the combinations was additive or synergistic (Figure 3.2.).  Combinations were 
synergistic at 1:1, 1:10, and 1:100 ratios (ZSTK474:erlotinib), but antagonistic 
effects were evident at 10:1 and 100:1 ratios (ZSTK474:erotinib) (Table 3.1.).  
Overall, while a synergistic interaction was observed with pan-PI3K and EGFR-
TKI inhibitors that impaired cell proliferation, we identified modest cytotoxic effect 
in the H460 cell line occurring at highest tandem drug concentrations.   
 
Synergistic combinations of EGFR-TKI and pan-PI3K inhibitor block 
proliferation in EGFR mutant/PTEN-null NSCLC  
The proliferative effects of erlotinib and ZSTK474 drug combinations were 
evaluated in the NSCLC cell line H1650 by Alamar Blue assay (Figure 3.3. A)  
H1650 cells were also found to be insensitive to single-agent erlotinib treatment, 
whereas the singe-agent pan-PI3K inhibitor was more effective at impairing 
proliferation after 72 hr exposure comparatively. Median effect analysis was 
calculated for each drug combination in order to assess inhibitory drug 
interactions (Figure 3.3. B). Our results for H1650 were similar to those found for 
A549 and H460, where synergistic interactions for ZSTK474:erlotinib ratios 
occurred at 1:1, 1:10 and 1:100, and antagonism in combinations where 
ZSTK474 concentrations exceeded the erlotinib concentrations (i.e. at ratios of 
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10:1, 100:1). Interestingly, at highest concentrations of erlotinib (30 and 3µM) we 
see identical responses to ZSTK474 combinations, each resulting in the 
complete blockade of proliferation and minor cytotoxicity.  
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Figure 3.1. Growth inhibition in KRAS mutant NSCLC induced by EGFR-TKI, 
erlotinib (ERL), and the pan-PI3K inhibitor, ZSTK474, alone and in 
combination. A549 and H460 cells were treated with indicated concentrations of 
each inhibitor, as single-agent, or in combination.  Combination data are 
presented as individual curves at fixed erlotinib concentrations (0.03 – 30µM) 
plotted against increasing ZSTK474 concentrations (0.03 – 30µM).  Points 
represent mean of three independent experiments ± S.D., and lines were fitted 
using non-linear regression analysis.  
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Figure 3.2.  Interaction of EGFR-TKI and pan-PI3K inhibitors in KRAS 
mutant NSCLC.  Median effect analysis was performed by CompuSyn software 
to study the interaction between the inhibitor combinations at the concentrations 
indicated in Figure 3.1. and Table 3.1.  Points represent the mean of three 
independent experiments.  Dotted lines mark range of interaction classification.  
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B. 
 
 
 
 
 
 
Figure 3.3.   Proliferative responses and inhibitor interactions to 
combination EGFR-TKI and pan-PI3K inhibition in EGFR mutant, PTEN-null 
NSCLC. (A) Combination effects on proliferation in EGFR mutant NSCLC.  Data 
presented as previously described in Figure 3.1. Points represent mean of three 
independent experiments ± S.D., and lines were fitted using non-linear 
regression analysis. (B) Interaction of EGFR-TKI and pan-PI3K in EGFR mutant 
NSCLC. Data are presented as previously described.  
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Table 3.1. Summary of drug combinations with corresponding 
combination indices.  Table summarizes calculated combination index value 
(CI) indicating individual concentrations of erlotinib (ERL) and ZSTK474 used in 
combination.   
 
 
 
 
 
A549 
ERL [µM] 
30 3 0.3 0.03 
ZS
TK
47
4 
[µ
M
] 30 0.62 1.58 1.99 2.08 
3 0.13 0.22 0.27 0.31 
0.3 0.11 0.15 0.28 0.44 
0.03 0.17 0.25 0.42 0.97 
      
      
H460 
ERL [µM] 
30 3 0.3 0.03 
ZS
TK
47
4 
[µ
M
] 30 0.52 1.22 1.65 1.84 
3 0.05 0.1 0.18 0.18 
0.3 0.02 0.08 0.2 0.211 
0.03 0.03 0.06 0.79 0.61 
      
      
H1650 
ERL [µM] 
30 3 0.3 0.03 
ZS
TK
47
4 
[µ
M
] 30 0.4 0.99 3.38 6.74 
3 0.18 0.27 1.06 3.09 
0.3 0.06 0.04 0.21 1.28 
0.03 0.03 0.01 0.03 0.18 
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3.5. DISCUSSION 
The intersection of signaling pathways involved in cancer has only 
recently been exploited for therapeutic gain.  The PI3K/AKT pathway and 
RAS/MAPK pathway both signal downstream of receptor tyrosine kinases, and 
are considered central mediators of oncogenic signaling in solid tumors [107]. 
Numerous targeted small molecule inhibitors are currently under development 
targeting various elements of these cascades such as EGFR, PI3K, AKT, RAF 
and MEK [103, 214].  However, tumors often have molecular aberrations 
affecting multiple signaling pathways making single-agent inhibitors ineffective.   
Both pre-clinical evidence and early phase clinical trials suggest that combination 
therapy may be a more effective strategy as compared to single-agent 
treatments.  Our experience with infectious diseases, such as HIV and 
tuberculosis, underscores the importance and success of drug combinations as 
therapeutic strategy [282] . 
In the current study, we investigated the combined pharmacological 
inhibition of EGFR and PI3K in NSCLC cell lines resistant to EGFR-TKI therapy.  
Cells harboring KRAS activating mutations rarely coexist with mutations affecting 
EGFR, and are largely considered de-novo resistant to single-agent EGFR-TKI 
therapy because RAS lies downstream of EGFR, thus oncogenic signaling 
through PI3K/AKT and MAPK pathways can persist despite EGFR activation 
[223].  H1650 cells are found to contain both mutant EGFR (DelE746-A750) and 
PTEN deletion.  Previous reports as well as observations in our lab have 
observed that cells harboring loss-of-function PTEN mutations are resistant to 
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EGFR inhibitors [172]. These studies demonstrate that in cells that are EGFR 
dependent, loss of PTEN may partially uncouple constitutive mutant EGFR 
signaling from downstream pathways PI3K/AKT and RAS/MAPK, thereby 
contributing to EGFR-TKI resistance.  Together, these support targeting the PI3K 
pathway may be effective strategy to impede proliferation in EGFR inhibitor 
resistant tumors. 
We have previously shown that all of the NSCLC cell lines (A549, H460, 
H1650) tested were sensitive to the single-agent pan-PI3K inhibitor ZSTK474.  
For KRAS-active A549 and H460, GI50 values 0.33µM and 0.15µM, and 
EGFR/PTEN mutant H1650 had GI50 at 0.69µM (Figure 2.3., Table 2.2.). Anti-
proliferative responses correlated with pharmacodynamic signaling as indicated 
by complete loss of pAKT signaling (Figure 2.5.). However, single-agent pan-
PI3K treatment did not induce apoptosis (Figure 2.9.).  These data also suggest 
that oncogenic signaling through PI3K/AKT may not be limited to any specific 
cancer genotype and suggests that constitutive pathway activation may be 
limiting efficacy of PI3K inhibitors.  We found that most EGFR-TKI and pan-PI3K 
inhibitor combinations tested in this study demonstrated marked synergistic 
growth inhibitory activity in all cell lines tested (Table 3.1.).  These observations 
support and extend previous in vitro data demonstrating that PI3K inhibitors used 
in combination with cytotoxic agents, as well as anti-EGFR and MEK inhibitors 
have improved anti-tumor activity relative to single-agent treatments [159, 283-
285].   
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When comparing dose response curves of drug combinations, we note 
distinct trend differences between the KRAS mutant and EGFR mutant NSCLC 
cell lines (Figure 3.1. and Figure 3.3.). Interestingly, among the KRAS mutant 
lines A549 are wild-type for PIK3CA, whereas H460 harbors (E545K) PIK3CA 
activating mutation, we do see an improved synergistic effect and cytotoxicity at 
higher drug combinations in H460 comparatively.  Both KRAS mutant cell lines 
fail to respond to increasing erlotinib doses, thus reduction in proliferation is 
largely in response to PI3K inhibition.  The opposite is observed in EGFR mutant 
H1650 cells. Proliferative capacity appears to be a function of EGFR-TKI 
concentration, not the PI3K inhibitor (Figure 3.3.).   
Whereas all combinations were growth inhibitory, we observed best drug 
synergism at ZSTK474: ERL drug ratios where 1:10, 1:100 1:1000 (Table 3.1.), 
suggesting lower doses of PI3K inhibitor combined with erlotinib at 
concentrations at or above GI50 may be therapeutically most effective.  Whereas, 
the combined treatments at reverse ratio had an antagonistic effect on cell 
proliferation (Table 3.1. and Figure 3.2.).    
To date, targeting tumors with PTEN alterations or KRAS-active cancers 
with PI3K inhibitors has yielded mixed results.  Neither of the two most studied 
pan-PI3K inhibitors, BKM-120 or GDC-0941, have demonstrated any preferential 
activity in vitro in PTEN-null cells [286, 287].  No responses to these drugs have 
been observed in patients bearing PTEN defective tumors in single-agent phase I 
trials [288].  Likewise, targeting KRAS mutant cancers with single-agent PI3K 
inhibitors have yet to demonstrate benefit [289].  A recent study identified tumors 
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having PIK3CA alterations or HER2 amplification were associated with sensitivity 
relative to those harboring PTEN or BRAF mutations, or tumors with concurrent 
PIK3CA and KRAS mutations which were all associated with resistance to the 
p110α selective inhibitor BYL719 [246].  For this reason, a potential strategy for 
treatment for KRAS-active cancers is largely focused on utilizing PI3K inhibitors 
in combination with MEK kinase inhibitors. 
Additionally, the presence of KRAS mutations has also been proposed to 
be a negative predictor for response to anti-EGFR therapies in lung cancer 
patients [271, 276, 290]. This however, is disputed as evidenced by the phase III 
SATURN trial among others, whereby KRAS mutant patients had improved 
survival and no negative effects from single-agent EGFR-TKI therapy [273].  
Inherent resistance to EGFR therapy is primarily associated with the absence of 
drug sensitizing mutations in EGFR, and to a lesser extent presence of other 
particular oncogenic molecules.  Thus, the predictive value associated with 
EGFR mutational status for selection of patients for EGFR-TKI therapy outweighs 
KRAS status as a potential negative predictor of clinical benefit [274].   Along 
with the added difficulty of identifying minor tumor subpopulations, and genetic 
variability among primary and metastatic sites, clinically there may be rationale 
for combining EGFR-TKI with a PI3K inhibitor as a maintenance treatment 
regardless of tumor genotype.   
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3.5 CONCLUSIONS 
From this investigation, we find that concurrent EGFR-TKI and pan-PI3K 
inhibition may be an effective therapeutic strategy sensitize tumors innately 
resistant to EGFR-TKI therapy.  We show that combinations act synergistically to 
sensitize KRAS mutant and EGFR/PTEN mutant NSCLC human tumor cells lines 
that improve cytostatic responses.  These effects also suggest that therapeutic 
resistance to PI3K kinase inhibitors may arise from upstream signaling through 
both wild-type and mutant EGFR.  These preclinical data may offer new 
strategies for clinical progress accelerating ever more efficient and tolerable 
cancer therapies.  Future study is needed to assess most effective scheduling of 
EGFR and PI3K inhibitors in order to better characterize and maximize observed 
synergistic effect on proliferation.  This is particularly important because 
antagonism was observed in combinations at higher concentrations of PI3K 
inhibitor.  Finally, additional controls representing normal lung epithelial cells 
should be included to provide early insight into issues of toxicity.    
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CHAPTER 4 
4.1. SUMMARY OF RESULTS 
The overarching hypothesis of this dissertation was that PI3K represents a 
clinically valuable molecular target for treatment of NSCLC.   
The first hypothesis, outlined in Chapter 2, was tested using NSCLC cell 
line models to characterize the activity of isoform-selective pharmacological and 
genetic inhibitors of PI3K as compared to pan-class I PI3K inhibition.  We 
identified that all class IA PI3K isoforms were expressed, albeit at differing levels 
among the cell lines tested, and having no correlation to known mutational 
status.  We demonstrate that isoform-selective inhibitors of PI3K were found to 
be capable of inhibiting PI3K/AKT signaling necessary for proliferation in some 
genetic contexts or cell types such as mutant PIK3CA (with A66) or in PTEN 
deficient tumors of the prostate (with TGX-221).  However, relative to pan-PI3K 
inhibition, all of NSCLC cell lines were resistant to isoform-selective PI3K 
inhibition, as reflected by micromolar GI50 values, and the inability to fully 
abrogate PI3K signaling. These results suggest that compensation among 
individual isoforms limit efficacy of isoform-selective inhibitors, and the presence 
of concurrent genetic aberrations further diminish any anti-tumor activity of PI3K 
inhibitors.  Evidence for isoform compensation was further confirmed through 
studies using siRNA-mediated knockdown of p110β.  Whereby the genetic loss 
of the p110β isoform alone had minor effects on PI3K/AKT signaling, and further 
signal attenuation was only partially achieved by addition of p110δ inhibitors.  
Finally, we identified that treatment with isoform-selective inhibitors and pan-PI3K 
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inhibitors are not cytotoxic, only producing a temporary cytostatic effect through 
G1 arrest.  This study highlights a fundamental dilemma for implementing 
isoform-selective inhibitors of PI3K, given that redundancy among the PI3K 
isoforms limit their effectiveness despite isoform expression levels and genetic 
context. 
In Chapter 3, given that isoform-selective inhibition of PI3K in NSCLC was 
ineffective relative to pan-PI3K inhibition, we investigated the utility of combined 
pan-PI3K and EGFR inhibition to overcome resistance associated with single 
pathway inhibition.  We hypothesized that simultaneously drugging the upstream 
surface receptor EGFR and PI3K may achieve more complete pathway control 
leading to improved anti-proliferative responses. The combination of pan-PI3K 
inhibitor, ZSTK474, and EGFR-TKI, erlotinib, resulted in synergistic blockade of 
proliferation in EGFR therapy resistant NSCLC cell lines.  Thus, combined 
blockade of PI3K and EGFR may represent an effective therapeutic strategy in 
both wild-type and EGFR activated tumors, and may enhance anti-proliferative 
responses in tumors harboring concurrent mutations affecting PIK3CA or PTEN. 
  
4.2. CONTRIBUTION TO THE FIELD 
This work contributes to the fundamental understanding of the PI3K 
signaling cascade, and its role as an oncogenic pathway in NSCLC.  The 
frequent activation of the PI3K/AKT pathway in cancer, and its critical role in 
tumor proliferation and survival make it a desirable target for drug discovery 
efforts.  However, the recent boom in PI3K inhibitor development and 
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diversification has made difficult direct comparisons between drugs, models, and 
strategies for ideal clinical and genomic contexts.  Our work addresses this 
important facet of targeted therapy, that being the ability for a drug (i.e. isoform-
selective or pan-PI3K inhibitor) to achieve sufficiently complete pathway 
inhibition, and if that can translate into anti-tumor activity at tolerable patient 
doses.  Through the characterization of in vitro activities of isoform-selective 
inhibitors we identified contexts whereby targeting particular isoforms may be 
clinically relevant and achievable, however isoform-selective inhibitors by design 
have poor selectivity for particular isoforms and consequently lack potency 
needed impede all PI3K signaling.  Expanding upon this, our work goes on to 
describe an inherent mechanism of resistance to PI3K inhibitors resulting from 
compensatory class IA isoform signaling.  Taken further, PI3K inhibitors have 
demonstrated promise when treated in combination with other therapies.  In our 
study, we sought to explore the potential of combining an EGFR-TKI with a pan-
PI3K inhibitor for treatment of EGFR therapy resistant NSCLC.  As previously 
discussed, tumors harboring EGFR kinase domain mutations demonstrate 
favorable responses to EGFR-TKI.    Because H1650 are EGFR (DelE746-A750) 
and PTEN deficient, targeting EGFR and PI3K in combination is a rational 
approach to overcoming PTEN mediated resistance to EGFR-TKI therapy.  This 
combination strategy was also effective at blocking proliferation of KRAS-active 
cancers, which currently have no therapeutic options.  There are a number of 
ways a cancer being wild-type EGFR and KRAS-active might be sensitized to 
combined EGFR-TKI and PI3K therapy.  First being the interconnected nature of 
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EGFR signaling downstream to PI3K/AKT and RAS/MAPK pathways.  
Pharmacological blockade of EGFR likely reduces the overall mitogenic signaling 
downstream of EGFR receptors.  Likewise, KRAS-active cancers signal 
downstream to both PI3K/AKT and MAPK pathways. Simultaneous inhibition of 
EGFR and PI3K, may reduce the overall oncogenic signaling downstream to both 
PI3K/AKT and RAS/MAPK pathways meanwhile the pan-PI3K inhibitor is able to 
fully block PI3K signaling.  The interconnected feedback activation or repression 
between these two pathways remains an active area of research and may also 
contribute to the synergistic interaction.  Finally, the PI3K blockade and potential 
reduction in RAS/MAPK signaling may negatively affect expression of ERBB 
family ligands, which may act to further reduce the overall contribution to 
proliferation by ERBB receptors.   Although continued work must be done in 
order to identify and dissect the mechanism of this drug combination, we are 
encouraged by these findings which necessitate further investigation of this drug 
combination in a mouse xenograft model as a logical next step.    Going forward 
further consideration must also be given to the optimal dosing conditions for each 
agent to achieve maximal therapeutic control while avoiding any associated 
toxicity. 
 
4.3. TRANSLATIONAL AND CLINICAL RELEVANCE 
The findings in this body of work hold substantial translational and clinical 
relevance as more PI3K inhibitors enter the clinical setting.  A key question this 
dissertation addresses is whether compounds targeting single PI3K isoforms can 
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provide significant single-agent efficacy in NSCLC cells that express multiple 
isoforms, and how those responses compare to those observed with pan-PI3K 
inhibitors.  We know that the PI3K/AKT pathway is important in cancer, and has 
great potential as a target for therapy.  This work is the first to evaluate the 
individual PI3K isoforms as targets for therapy in genetically diverse NSCLC 
models. 
Ultimately, for successful translation from cell culture models to the clinical 
implementation of rationally selected of single or combined targeted therapeutics, 
there must be characterization of pharmacodynamic and pharmacokinetic 
responses to single- and dual-agent therapy. Our work dissects the preclinical 
biomarkers for drug activity to assess the pharmacodynamic and kinetic 
responses to PI3K inhibition to better identify NSCLC subtypes sensitive to these 
drugs.  Through this characterization we identified considerable redundancy 
among class IA PI3K isoforms for sustaining proliferation and survival. This 
represents a challenge for development of isoform-selective inhibitors, and calls 
into question the necessity for even more diversified PI3K inhibitor selectivity 
profiles.  We speculate there may in fact be an advantage to developing a 
p110α/β selective inhibitors that target isoforms most highly expressed in solid 
tumor tissues of origin, and do not target the p110δ and p110γ isoforms, which 
would likely spare immune cells and avoid related toxicity.     However, taken 
together we determined that isoform-selective inhibitors will likely fail in a clinical 
setting due to incomplete negative regulation of PI3K signaling.   
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Lastly, substantial evidence suggest single-agent inhibitors are ineffective 
as anti-cancer agents due to either lack of response or acquired resistance to 
drug [8,13-16].  Therefore, greater clinical responses may be realized through 
combinations of PI3K inhibitors with other targeted therapies.  There is already 
emerging clinical support for this approach, for example the promising results 
combination study using the pan-PI3K inhibitor GDC-0941 with the HER2 
directed therapy, trastuzumab, that was found also effective in trastuzumab-
resistant cell models [291, 292].  Similarly, combining EGFR and PI3K inhibition 
could improve sensitivity in EGFR therapy resistant NSCLC.  Utilizing two models 
for innate EGFR therapy resistance; we found concurrent blockade of EGFR and 
PI3K can synergistically block KRAS mutant NSCLC proliferation.   This 
revelation is particularly important because KRAS driven tumors are the most 
common single-driver mutations found in advanced NSCLC, and currently there 
are no therapeutic options for these patients.  The EGFR/PI3K inhibitor 
combination was also found to be effective in EGFR active NSCLC that are 
resistant to targeted EGFR inhibitors due to the functional loss of PTEN.  This 
model underscores how in advanced cancers having multiple pathway defects, 
single-agent targeted therapies are ineffective due to uncoupled dependence 
(“loss of oncogene addiction”) for a single driver such as EGFR.   Thus permitting 
sustained pathway activation and the opportunity for pathway cross-talk. As a 
result of these studies, we hypothesize an overall initial increase in partial clinical 
responders to the combination, by sensitizing previously resistant NSCLC 
subtypes.  We also predict that in EGFR-sensitive NSCLC, this combination 
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could also minimize or reduce the eventual selective pressure for the 
development and outgrowth of EGFR-TKI resistance by blocking reactivation of 
PI3K/AKT pathway.   Slowing tumor reinitatiation even by a single month would 
represent a significant clinical breakthrough in NSCLC patients having acquired 
resistance to EGFR therapy.    
As summarized above, the translational promise of this combination 
strategy targeting PI3K and EGFR are manifold.   Foremost being those patients 
who currently have little or no therapeutic options, such as those harboring 
KRAS-active cancers.  Secondly, as compared to front line cytotoxic therapies, 
the optimized use of orally available targeted inhibitors combination will likely 
represent a more convenient and tolerable treatment regimen.  Finally, for 
patients receiving benefit from EGFR directed therapy, the addition of a PI3K 
inhibitor may improve duration of response relative to current single-agent 
therapy.  
 
4.4. CONCLUSIONS 
In conclusion, we were unable to prove our hypothesis that activated PI3K 
is a good single-agent target for treatment of NSCLC.  We find that isoform-
selective PI3K inhibitors lack potency relative to pan-PI3K inhibitors due to 
redundancies among isoform signaling.   Although superior to isoform selective 
inhibitors, treatment with the pan-PI3K inhibitor alone had only temporary 
cytostatic anti-tumor activity.  Importantly, we identified that targeting PI3K in 
combination with an EGFR inhibitor may offer potential benefit in both KRAS 
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active, EGFR wild-type, and in EGFR mutant NSCLC.  We conclude that the 
value of PI3K as a therapeutic target will not be realized through monotherapy, 
but rather when PI3K inhibitors are utilized in combination with other rationally 
selected targeted agents.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Chris W. Stamatkin 2014 
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APPENDIX 
APPENDIX I: SUPPLEMENTARY FIGURES FOR CHAPTER 2 
 
 
 
 
  
 
 
Table 2.3.   Measurement of cell proliferation in synchronized NSCLC cell 
lines after PI3K inhibitor treatment. Cell lines A549, PC9, H1650, H1975 and 
H460 cells were treated with increasing concentrations (0.3 - 30 μM) of isoform 
specific inhibitors A66, TGX-221, CAL-101 and IC488743.  Cell proliferation was 
determined by trypan blue exclusion assay after 72 hr treatment.  Data is 
representative of 2 independent experiments (n=2). Experimental results were 
normalized to cells serum starved for 24 hr prior to treatment cells and divided by 
untreated control to determine (% growth relative to control).   Non-linear curve 
fitting and GI50 values were generated using Graphpad Prism. 
 
 
 
GI50 values of PI3K inhibitors for NSCLC cell lines 
GI50 (µM) A549 H460  H1975  PC9  H1650  
Isoform-selective PI3K inhibitors 
A66 5.2 1.27 2.61 7.55 42.08 
TGX-221 >100 30.41 25.93 >100 3.58 
CAL-101 16.9 35.94 3.49 3.70 6.04 
IC488743 4.2 3.86 7.22 13.23 7.84 
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